ROCK kinase inhibitors

Abstract

The present invention relates to compounds that inhibit ROCK activity. In particular, the present invention relates to compounds, pharmaceutical compositions, and methods of use, such as methods for inhibiting ROCK activity and treating, for example, cerebral cavernous hemangioma syndrome (CCM) and cardiovascular disease, using the compounds and pharmaceutical compositions of the present invention.

Description

[Technical field]

[0001] The present invention relates to compounds that are Rho-associated protein kinase (ROCK) inhibitors. In particular, the present invention relates to compounds that selectively inhibit the activity of ROCK, pharmaceutical compositions containing the compounds, and methods of use therefor. [Background technology]

[0002] ROCK is a key RhoA effector involved in the regulation of multiple cell signaling pathways through phosphorylation of multiple substrates, including myosin light chain (MLC), LIM kinase, MYPT1, and CPI-17. ROCK substrates are involved in smooth muscle contractility, vascular permeability, actin filament organization, cell adhesion, cell migration, growth control, and cytokine formation. The direct involvement of ROCK in smooth muscle contractility is due to increased phosphorylation of both MLC, which increases contractility upon phosphorylation, and MLC-phosphatase, which is inhibited upon phosphorylation, which further increases activation of MLC-phosphorylated ROCK, thus resulting in increased smooth muscle contractility.

[0003] Literature reports suggest an association between ROCK activity and a number of cardiovascular diseases related to vascular disorders including hypertension, atherosclerosis, ischemic stroke, coronary vasospasm, cerebral vasospasm, angina pectoris, erectile dysfunction, and renal disease, as well as other smooth muscle hyperreactivity such as glaucoma and asthma.

[0004] Cerebral cavernous hemangioma (CCM) syndrome is a disease associated with defective endothelial junctions, mainly in the brain, which puts patients at a lifelong risk of seizures, hemorrhagic strokes, and other neurological defects.Cerebral cavernous hemangioma (CCM) is a vascular malformation found mainly in the central nervous system, for example, in the brainstem and spinal cord, and can occur in sporadic or autosomal dominant forms, the latter of which maps to three gene loci, KRIT-1 / CCM1, MGC4607 / OSM / CCM2, and PDCD10 / CCM3 (see, for example, Glading et al., (2007) J. Cell Biol. 179: 247-254).

[0005] CCM1, CCM2, and CCM3 proteins each interact with several proteins, including Rap1, a RhoA-GTPase. Rap1 plays a role in regulating the actin cytoskeleton by stimulating the formation of actin fibers. Inactivating mutations in CCM1, CCM2, or CCM3 are sufficient to induce CCM vascular pathology by inhibiting endothelial cell vascular-like tube formation and extracellular matrix invasion, leading to weakening of cell-cell junctions and increased leakage from blood vessels. Loss of expression of CCM1, -2, or -3 proteins causes significant overexpression and increased activation of Rap1. Increased Rap1 activation is associated with increased Rho kinase-dependent (ROCK) phosphorylation and short hairpin RNA knockdown of endothelial cells rescued by ROCK from CCM pathology (see, e.g., Borikova et al., (2010) J. Biol. Chem. 285:11760-11764).

[0006] Unfortunately, patients with CCM have limited treatment options, and there are no approved drugs in the United States to treat CCM. Fasudil hydrochloride, an isoquinoline sulfonamide derivative, is a potent ROCK inhibitor approved outside the United States to treat symptoms of cerebral vasospasm and cerebral ischemia after subarachnoid hemorrhage. Fasudil is used off-label by physicians to treat CCM, presumably by inhibiting ROCK kinase activity, but fasudil, which exhibits lower selectivity than other AGC family kinases, also exhibits several severe toxic side effects and drawbacks, including forced short-term treatment, low oral bioavailability, cytotoxicity, and blood pressure fluctuations (see, e.g., Xin et al., (2015) BioSci Rep. 35:1-13).

[0007] There is a significant unmet medical need to treat patients with CCM and, more broadly, numerous other diseases associated with elevated smooth muscle contractility, such as cardiovascular disease, and there is strong evidence pointing to selective ROCK kinase inhibitors as a potential source for pharmacological therapeutic intervention. Concomitantly, there is a need to develop new ROCK kinase inhibitors that have improved therapeutic times, improved oral bioavailability, reduced cytotoxicity, and reduced off-target activity, especially over AGC family kinase members. [Prior art documents] [Non-patent literature]

[0008] [Non-Patent Document 1] Glading et al.,(2007)J.Cell Biol.179:247-254 [Non-Patent Document 2] Borikova et al.,(2010)J.Biol.Chem.285:11760-11764 [Non-Patent Document 3] Xin et al.,(2015)BioSci Rep.35:1-13 Summary of the Invention

[0009] The present inventors have recognized a need to develop new ROCK kinase inhibitors that demonstrate improved cellular potency, kinome selectivity, efficacy, stability, and safety. The compounds and compositions of the present invention advantageously overcome one or more of these shortcomings by providing potent, selective, and orally active ROCK inhibitors.

[0010] In one aspect of the present invention, compounds are provided that inhibit ROCK kinase activity. In certain embodiments, the compounds are represented by formula (Ia), formula (Ib), formula (IIa), or formula (IIb): [ka]

[0011] or a pharma- ceutically acceptable salt thereof,

[0012] During the ceremony,

[0013] X is a partially saturated aza-containing heteroaryl;

[0014] Y is N or CH;

[0015] Each R 1 is cyano, hydroxyl, hydroxyalkyl, halogen, haloalkyl, alkoxy, Q-C1-C3 alkyl, -N(R 4 )2, -NR 4 C(O)C1-C3 alkyl or cycloalkyl;

[0016] Q is a bond, O, or N;

[0017] Each R 2 is hydrogen or a halogen,

[0018] Each R 3 is hydrogen, halogen, or C1-C3 alkyl;

[0019] Each R 4 is hydrogen or C1-C3 alkyl,

[0020] m is 0, 1, 2, or 3.

[0021] In another aspect of the present invention, there is provided a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (Ia), Formula (Ib), Formula (IIa), or Formula (IIb), and a pharma- ceutically acceptable excipient, salt, solvate, carrier, and / or diluent.

[0022] In yet another aspect, the present invention is directed to a method of treating a cardiovascular disease associated with increased vascular tone comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (Ia), Formula (Ib), Formula (IIa), or Formula (IIb), or a pharmaceutical composition comprising such a compound. In one embodiment, the cardiovascular disease is hypertension, atherosclerosis, ischemic stroke, coronary vasospasm, cerebral vasospasm, angina pectoris, and erectile dysfunction.

[0023] In yet another aspect, the present invention is directed to a method of treating diseases associated with elevated non-vascular smooth muscle contractility comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (Ia), Formula (Ib), Formula (IIa), or Formula (IIb), or a pharmaceutical composition comprising such a compound. In one embodiment, diseases associated with elevated non-vascular smooth muscle contractility asthma and glaucoma.

[0024] In yet another aspect of the present invention, there is provided a method for inhibiting ROCK activity in a cell, comprising contacting the cell with a compound of formula (Ia), (Ib), (IIa), or (IIb).Also provided is a method for treating CCM in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (Ia), (Ib), (IIa), or (IIb), or a pharmaceutical composition comprising such a compound. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] The present invention relates to ROCK kinase inhibitors. In particular, the present invention relates to compounds that selectively inhibit the activity of ROCK kinase, pharmaceutical compositions containing therapeutically effective amounts of the compounds, and methods of use thereof, such as methods for treating cerebral cavernous hemangioma syndrome (CCM) and cardiovascular disease.

[0026] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs.All patents, patent applications, and publications mentioned herein are incorporated by reference to the extent that they are consistent with this disclosure.Terms and scopes have the definitions generally defined unless otherwise expressly defined.

[0027] For simplicity, chemical moieties are defined and referred to throughout primarily as monovalent chemical moieties (e.g., alkyl, aryl, etc.). Nevertheless, such terms may also be used to convey corresponding multivalent moieties under appropriate structural circumstances apparent to one of skill in the art. All atoms are understood to have their normal valency for bond formation (i.e., 4 for carbon, 3 for N, 2 for O, and 2, 4, or 6 for S, depending on the oxidation state of S).

[0028] As used herein, "ROCK kinase" refers to members of the Rho-associated protein kinase ("ROCK") family, including ROCK1 and ROCK2 kinases.

[0029] As used herein, "ROCK inhibitor" refers to the compounds of the present invention represented by formula (I) or (II) described herein. These compounds can negatively regulate or inhibit all or part of the enzymatic activity of ROCK kinase.

[0030] The term "alkyl" as used herein refers to straight and branched chain aliphatic groups having 1 to 12 carbon atoms. Thus, "alkyl" includes C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, 10 , C 11 , and C 12 Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl.

[0031] The term "cyano" refers to --CN.

[0032] The term "cycloalkyl" as used herein refers to saturated and partially unsaturated cyclic hydrocarbon groups having 3 to 12 carbons. Thus, "cycloalkyl" refers to C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C210, C220, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, ​​C47, C48, C49, C50, C51, C52, C53, C54, C55, C56, C57, 10 , C 11 , and C 12 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.

[0033] As used herein, the term "heteroaryl" refers to a group having 5 to 14 ring atoms, preferably 5, 6, 10, 13, or 14 ring atoms, having 6, 10, or 14 pi electrons shared in a cyclic array, and, in addition to carbon atoms, having 1 to 3 heteroatoms, each independently N, O, or S. "Heteroaryl" also includes fused polycyclic (e.g., bicyclic) ring systems in which at least one ring is aromatic and one or more of the fused rings is non-aromatic, provided that at least one ring contains an N, O, or S ring atom.

[0034] Examples of heteroaryl groups include acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzo[d]oxazol-2(3H)-one, 2H-benzo[b][1,4]oxazin-3(4H)-one, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, furanyl, and furanyl. Zanyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl , oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidyl nyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienoxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, and xanthenyl.

[0035] The term "aza-containing heteroaryl" refers to a heteroaryl group having 5-14 ring atoms, preferably 5, 6, 10, 13, or 14 ring atoms, and containing nitrogen atoms in place of carbon atoms in a monocyclic, bicyclic, polycyclic, or fused group having 6, 10, or 14 pi-electrons shared in a cyclic array. "Aza-containing heteroaryl" also includes fused polycyclic (e.g., bicyclic) ring systems in which at least one ring is aromatic and at least one ring contains N, and one or more of the fused rings are non-aromatic.

[0036] Exemplary aza-containing heteroaryl groups include indolizinyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, indazolyl, 1H-indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinolidinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, quinuclidinyl, carbazolyl, acridinyl, phenadimyl, fluoro, fluorophenyl ... Examples include, but are not limited to, ethynyl, phenoxazinyl, 2H-pyrrolyl, pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, oxazolyl, thiazolyl, imidazolyl, 2-imidazolinyl, pyrazolyl, 2-pyrazolinyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, or 1,3,5-triazinyl.

[0037] The term "haloalkyl" refers to an alkyl chain in which one or more hydrogens have been replaced with a halogen. Exemplary haloalkyls are trifluoromethyl, difluoromethyl, fluorochloromethyl, and fluoromethyl.

[0038] The terms "halogen" or "halo" as used herein refer to chlorine, bromine, fluorine, or iodine.

[0039] The term "hydroxyl" refers to --OH.

[0040] The term "hydroxyalkyl" refers to -alkyl-OH.

[0041] As used herein, an "effective amount" of a compound is an amount sufficient to negatively regulate or inhibit the activity of a ROCK kinase.

[0042] As used herein, a "therapeutically effective amount" of a compound is an amount sufficient to ameliorate or in any way reduce the symptoms, or to halt or reverse the progression of a condition, such as CCM, or to negatively regulate or inhibit the activity of ROCK kinase. Such an amount may be administered as a single dose or may be administered according to a regimen, whereby it is effective.

[0043] As used herein, "treatment" means any manner in which the symptoms or pathology of a patient's condition, disorder, or disease are ameliorated or otherwise beneficially altered.

[0044] As used herein, amelioration of symptoms of a particular disorder by administration of a particular compound or pharmaceutical composition refers to permanent or temporary, sustained or transient relief that may result from or be associated with administration of the composition. compound

[0045] In one aspect of the present invention, a compound represented by formula (Ia), (Ib), (IIa), or (IIb): [ka]

[0046] or a pharma- ceutically acceptable salt thereof,

[0047] During the ceremony,

[0048] X is a partially saturated aza-containing heteroaryl;

[0049] Y is N or CH;

[0050] Each R 1 is cyano, hydroxyl, hydroxyalkyl, halogen, haloalkyl, alkoxy, Q-C1-C3 alkyl, -N(R 4 )2, -NR 4 C(O)C1-C3 alkyl or cycloalkyl;

[0051] Q is a bond, O, or N;

[0052] Each R 2 is hydrogen or a halogen,

[0053] Each R 3 is hydrogen, halogen, or C1-C3 alkyl;

[0054] Each R 4 is hydrogen or C1-C3 alkyl,

[0055] m is 0, 1, 2, or 3.

[0056] In one embodiment of the invention, X is selected from the group consisting of indolizinyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, indazolyl, 1H-indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinolidinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, quinuclidinyl, carbazolyl, acridinyl, phenazimyl, phenothiazinyl, and the like. In one embodiment, X is an aza-containing heteroaryl selected from R 1 It is a substituted indolin-1-yl.

[0057] In one embodiment, X is [ka]

[0058] where m, Y, and R 1 is as defined herein.

[0059] In one embodiment, m is 1 and R 1 is cyano, hydroxyl, hydroxyalkyl, halogen, haloalkyl, alkoxy, Q-C1-C3 alkyl, -N(R 4 )2, -NR 4 C(O)C1-C3 alkyl, or cycloalkyl.

[0060] In one embodiment, R 1 is cyano. In one embodiment, R 1 is hydroxyl. In one embodiment, R 1 is a halogen. In one embodiment, the halogen is chlorine or fluorine. In one embodiment, R 1 is haloalkyl. In one embodiment, haloalkyl is trifluoromethyl. In one embodiment, R 1 is Q-C1-C3 alkyl. In one embodiment, Q is a bond and C1-C3 alkyl is methyl, ethyl, or isopropyl. In one embodiment, R 1 is Q-C1-C3 alkyl, where Q is O and C1-C3 alkyl is methyl, ethyl, or isopropyl. 1 is Q-C1-C3 alkyl, where Q is N and C1-C3 alkyl is methyl, ethyl, or isopropyl. 1 is hydroxyalkyl, where hydroxyalkyl is hydroxymethyl. In one embodiment, R 1 is alkoxy. In one embodiment, alkoxy is methoxy. In one embodiment, R 1 is -N(R 4In one embodiment, each R 4 In one embodiment, each R 4 The group is a C1-C3 alkyl. In one embodiment, R 1 -NR 4 C(O)C1-C3 alkyl. In one embodiment, R 4 The group is hydrogen and the C1-C3 alkyl is methyl. 1 is cycloalkyl, where cycloalkyl is cyclopropyl.

[0061] In one embodiment, m is 2 and each R 1 are independently cyano, hydroxyl, hydroxyalkyl, halogen, haloalkyl, alkoxy, Q-C1-C3 alkyl, -N(R 4 )2, -NR 4 C(O)C1-C3 alkyl, or cycloalkyl. In certain embodiments, each R 1 is halogen. In one embodiment, one R 1 is cyano, and the other R 1 is hydroxyl, hydroxyalkyl, halogen, haloalkyl, alkoxy, Q-C1-C3 alkyl, -N(R 4 )2, -NR 4 C(O)C1-C3 alkyl, or cycloalkyl.

[0062] In one embodiment, X is [ka]

[0063] where each R 1 is hydrogen or methyl. In one embodiment, each R 1 is methyl.

[0064] In one embodiment, R 2 is a halogen. In certain embodiments, the halogen is chlorine.

[0065] In one embodiment, R3 is halogen or C1-C3 alkyl. In certain embodiments, halogen is fluorine. In other embodiments, R 3 is C1-C3 alkyl, where C1-C3 alkyl is methyl.

[0066] In certain embodiments, the compound of formula (Ia), formula (Ib), formula (IIa), or formula (IIb) is [ka] [ka] [ka]

[0067] as well as pharma- ceutically acceptable salts of the foregoing compounds.

[0068] The compounds of Formula (Ia), Formula (Ib), Formula (IIa), or Formula (IIb) can be formulated into pharmaceutical compositions.

[0069] The compounds disclosed herein include all pharma- ceutically acceptable isotopically labeled compounds in which one or more atoms of the compounds disclosed herein are replaced by an atom having the same atomic number and an atomic mass or mass number different from the atomic mass or mass number normally found in nature. Examples of isotopes that can be incorporated into the compounds disclosed herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, e.g. 2 H, 3 H, 11 C. 13 C. 14 C. 13 N, 15 N, 15 O. 17 O. 31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I, and125 I. Such radiolabeled compounds may be useful, for example, to help determine or measure the effectiveness of compounds by characterizing binding affinity and kinetics to ROCK, as well as other modes of action. Certain compounds of the present disclosure also contain tritium, 3 H, and carbon-14, 14 When labeled with a radioisotope such as C, it can be useful in characterizing drug distribution and in vivo tissue expression of ROCK.

[0070] deuterium, 2 When labeled with heavier isotopes, such as H, the compounds disclosed herein may exhibit therapeutic advantages such as greater metabolic stability, resulting in longer in vivo half-lives, which in turn can reduce therapeutic dosing requirements.

[0071] To better characterize substrate receptor occupancy or tissue expression in living specimens, either statically or longitudinally, the atoms of the compounds disclosed herein may be 11 C. 14 F, 15 O, and 13 Substitution with a positron-emitting isotope such as N may enable positron emission tomography (PET) studies.

[0072] The isotopically labeled compounds disclosed herein can be prepared by conventional techniques known to those of skill in the art, or by processes analogous to those described in the relevant Examples and Schemes, substituting an appropriate isotopically labeled reagent for a previously used non-labeled reagent.

[0073] Some of the compounds disclosed herein may exist as stereoisomers.The compounds disclosed herein include all stereoisomers, both as pure individual stereoisomer preparations and as enriched preparations, as well as racemic mixtures of such stereoisomers and individual diastereomers and enantiomers that can be separated according to methods known to those skilled in the art.Furthermore, the compounds disclosed herein include all individual tautomeric states of the compounds and their mixtures.

[0074] Pharmaceutical Compositions In another aspect, the present invention provides a pharmaceutical composition comprising the ROCK kinase inhibitor according to the present invention and a pharma- ceutically acceptable carrier, excipient, or diluent.The compounds of the present invention can be formulated by any method known in the art and prepared for administration by any route, including but not limited to parenteral, oral, sublingual, transdermal, topical, subcutaneous, intranasal, intratracheal, or intrarectal.In certain embodiments, the compounds of the present invention are administered intravenously in a hospital environment.In certain other embodiments, administration may be preferably by oral route.

[0075] The characteristics of the carrier depend on the route of administration. As used herein, the term "pharmaceutical acceptable" refers to a non-toxic material that is compatible with a biological system, such as a cell, a cell culture, a tissue, or an organism, and does not interfere with the effectiveness of the biological activity of the active ingredient(s). Thus, the composition according to the present invention may contain, in addition to the inhibitor, diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The preparation of pharmaceutical acceptable formulations is described, for example, in Remington's Pharmaceutical Sciences, 18th Edition, ed. A. Gennaro, Mack Publishing Co., Easton, Pa., 1990.

[0076] As used herein, the term pharma-ceutically acceptable salt refers to the salt that retains the desired biological activity of the above-identified compound and shows minimal or no undesired toxicological effects.Examples of such salts include, but are not limited to, the acid addition salts formed with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, etc.), and the salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, and polygalacturonic acid. The compounds may also be administered as pharma- ceutically acceptable quaternary salts known to those of skill in the art, specifically including quaternary ammonium salts of the formula --NR+Z-, where R is hydrogen, alkyl, or benzyl, and Z is a counterion that includes chloride, bromide, iodide, --O-alkyl, toluenesulfonate, methylsulfonate, sulfonate, phosphate, or carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, malate, citrate, tartrate, ascorbate, benzoate, cinnamate, mandelate, benzilate, and diphenylacetate).

[0077] The active compound is contained in a pharma- ceutically acceptable carrier or diluent in an amount sufficient to deliver a therapeutically effective amount to the patient without causing serious toxic effects to the patient being treated. Doses of active compound for all of the above conditions range from about 0.01 to 300 mg / kg, preferably 0.1 to 100 mg / kg / day, more commonly 0.5 to about 25 mg per kilogram of recipient body weight per day. Typical topical doses will be in the range of 0.01 to 3% weight / weight in a suitable carrier. Effective dosage ranges of pharma- ceutically acceptable derivatives can be calculated based on the weight of the parent compound to be delivered. If the derivative is active in itself, the effective dosage can be estimated as above using the weight of the derivative or by other means known to those skilled in the art.

[0078] Pharmaceutical compositions containing the compounds of the invention can be used in the methods described herein.

[0079] How to use In yet another aspect, the invention provides a method for inhibiting ROCK activity in a cell, comprising contacting a cell in which inhibition of ROCK activity is desired with a therapeutically effective amount of a compound of Formula (Ia), Formula (Ib), Formula (IIa), or Formula (IIb), a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or a pharma- ceutically acceptable salt thereof.

[0080] The compositions and methods provided herein are deemed particularly useful for inhibiting ROCK activity in cells. In one embodiment, a cell in which inhibition of ROCK activity is desired is contacted with an effective amount of a compound of formula (Ia), formula (Ib), formula (IIa), or formula (IIb) to negatively regulate the activity of ROCK kinase. In other embodiments, a therapeutically effective amount of a pharma- ceutically acceptable salt or pharmaceutical composition containing a compound of formula (Ia), formula (Ib), formula (IIa), or formula (IIb) can be used. In certain embodiments, contacting a cell with an effective or therapeutically effective amount of a compound of formula (Ia), formula (Ib), formula (IIa), or formula (IIb) occurs in vivo. In certain embodiments, contacting a cell with an effective or therapeutically effective amount of a compound of formula (Ia), formula (Ib), formula (IIa), or formula (IIb) occurs in vitro. In one embodiment, the therapeutically effective amount of the compound of Formula (Ia), Formula (Ib), Formula (IIa), or Formula (IIb) is between about 0.01-300 mg / kg per day. In one embodiment, the therapeutically effective amount of the compound of Formula (Ia), Formula (Ib), Formula (IIa), or Formula (IIb) is between about 0.1-100 mg / kg per day.

[0081] In one embodiment, the compound of formula (Ia), formula (Ib), formula (IIa), or formula (IIb) preferentially inhibits the activity of ROCK2 kinase over ROCK1 kinase. In another embodiment, the compound of formula (Ia), formula (Ib), formula (IIa), or formula (IIb) inhibits the activity of ROCK2 kinase and ROCK1 kinase to the same extent. In one embodiment, the therapeutically effective amount of the compound of formula (Ia), formula (Ib), formula (IIa), or formula (IIb) is between about 0.01-300 mg / kg per day. In one embodiment, the therapeutically effective amount of the compound of formula (Ia), formula (Ib), formula (IIa), or formula (IIb) is between about 0.1-100 mg / kg per day.

[0082] In one embodiment, a method is provided for treating a patient having cerebral cavernous hemangioma syndrome (CCM), comprising administering to the patient a therapeutically effective amount of a compound of Formula (Ia), Formula (Ib), Formula (IIa), or Formula (IIb), or a pharma- ceutically acceptable salt thereof, alone or in combination with a pharma- ceutically acceptable carrier, excipient, or diluent.

[0083] In another embodiment, a method of treating a cardiovascular disease associated with increased vascular tone is provided, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (Ia), Formula (Ib), Formula (IIa), or Formula (IIb), or a pharmaceutical composition thereof. In one embodiment, the cardiovascular disease is hypertension, atherosclerosis, ischemic stroke, coronary vasospasm, cerebral vasospasm, angina pectoris, and erectile dysfunction.

[0084] In an embodiment, a method of treating a disease associated with elevated non-vascular smooth muscle contractility is provided, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (Ia), (Ib), (IIa), or (IIb), or a pharmaceutical composition thereof. In one embodiment, diseases associated with elevated non-vascular smooth muscle contractility asthma and glaucoma.

[0085] By negatively regulating the activity of ROCK, particularly in the case of cells that overexpress the ROCK enzyme or an autosomal dominant mutation that activates the ROCK enzyme, the method is designed to regulate the activity of ROCK, in some embodiments inhibit the formation of new CCMs and / or reduce or eradicate existing CCMs in treated patients, or treat certain cardiovascular diseases or diseases associated with elevated non-vascular smooth muscle contractility. The cells / patients can be contacted with a single dose or multiple doses according to a specific treatment regimen to provide the desired negative regulation of ROCK. For example, the size and number of CCMs can be monitored using well-known methods, including CT scanning or MRI scanning, to assess the effectiveness of the treatment, and the dosage can be adjusted accordingly by the attending physician.

[0086] The concentration and route of administration to patients may vary according to the severity of disease.The compound, its pharmaceutically acceptable salt, and pharmaceutical compositions containing such compounds and salts may also be co-administered with other compounds, or used as adjuvants either before or after surgery, in combination with other treatments, such as surgical intervention.The degree of ROCK kinase inhibition can be monitored in patients using well-known assay methods, including the method of Example A, to access the effectiveness of treatment, along with other cranial imaging techniques and equipment, such as CT scan, MRI, X-ray, etc., and dosage can be adjusted by the attending physician accordingly.

[0087] Reaction Schemes and Examples The compounds of the invention can be prepared using commercially available reagents using the synthetic methods and reaction schemes described herein, or using other reagents and conventional methods well known to those of skill in the art.

[0088] For example, compounds of the present invention can be prepared according to general reaction schemes I and II. [ka]

[0089] Scheme I illustrates the preparation of compounds of formula (I) of the present invention. 2 Substituted haloisoquinoline A undergoes electrophilic aromatic substitution reaction with sulfuric acid at elevated temperature to give halosulfonated intermediate B (Step 1). Reaction of halosulfonated intermediate B under acidic conditions, e.g., HCl, and elevated temperature, gives sulfonate-substituted isoquinolinone C (Step 2). The sulfonic acid is typically converted to the sulfonyl chloride using sulfuryl chloride in DMF at low temperature (Step 3). R 1 Addition of a substituted aza-containing heteroaryl X typically proceeds under basic conditions using a suitable base such as TEA in a solvent such as DCM to give compound E of formula (I) (Step 4). [ka]

[0090] Scheme II illustrates the preparation of compounds of formula (II) of the present invention, wherein R 3 is C1-C3 alkyl. Nitration of the halo-substituted isoquinoline A is carried out using nitric acid in the presence of sulfuric acid at low temperature, e.g., 0° C., to produce the nitro-substituted compound B. 3 B(OH) is coupled to intermediate B via a Suzuki reaction using a suitable palladium catalyst, such as Pd(dddf)Cl, in the presence of a suitable base, such as CsCO in dioxane, to give R. 3 A substituted compound C is produced. The nitro-containing compound C is reduced to an amine D. The amine D is reacted with sodium nitrite under acidic conditions and then treated with CuCl2 and SO2 to give the sulfonyl chloride E. 1 Addition of a substituted aza-containing heteroaryl X typically proceeds under basic conditions using a suitable base such as TEA in a solvent such as DCM to give compound F. Reaction with m-CPBA gives N-oxide G. Treatment of N-oxide G with acetic anhydride with heating gives acetic acid, which undergoes spontaneous 2,3-sigmatropic rearrangement. Deprotection of the acetate provides the 1-oxo compound H.

[0091] The following examples are intended to illustrate more specific embodiments of the invention, but are not intended to limit the scope of the invention. [ka]

[0092] Compound 1-2: A solution of 1-chloroisoquinoline (5 g, 30.5 mmol) in sulfonic acid chloride (50 mL, 750.9 mmol) was stirred at 150 °C for 12 h under N2 atmosphere. The reaction mixture was quenched by adding ice, then diluted with H2O (300 mL) and extracted with DCM (100 mL × 3). The combined organic layers were washed with saturated brine (300 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether: ethyl acetate = 0: 1 to 10: 1). Compound 1-2, 1-chloroisoquinoline-5-sulfonyl chloride (19.1 g, 72.9 mmol, 47.7% yield) was obtained as a yellow solid.

[0093] Compound 1-3: A solution of 1-chloroisoquinoline-5-sulfonyl chloride (2.5 g, 9.54 mmol) in aqueous HCl (30 mL, 9N, 276.9 mmol) was stirred at 100° C. under N2 atmosphere for 12 h. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The crude product, compound 1-3, 1-hydroxyisoquinoline-5-sulfonic acid (2.8 g, crude) was obtained as a yellow solid and used in the next step without further purification.

[0094] Compound 1-4: To a solution of 1-hydroxyisoquinoline-5-sulfonic acid (0.8 g, 3.55 mmol) in SOCl2 (40 mL) was added DMF (273 μL, 3.55 mmol) at 0° C., and the mixture was stirred at 15° C. for 30 min under N2 atmosphere. The mixture was then stirred at 35° C. for 2.5 h under N2 atmosphere. The reaction mixture was diluted with H2O (100 mL) and extracted with DCM (200 mL×3). The combined organic layers were washed with saturated brine (100 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The crude product, compound 1-4, 1-hydroxyisoquinoline-5-sulfonyl chloride (0.3 g, 1.23 mmol, 34.6% yield) was obtained as a yellow solid. This compound was used in the next step without further purification. Example 1: To a solution of 1-hydroxyisoquinoline-5-sulfonyl chloride (150 mg, 615.6 μmol) in DCM (10 mL), TEA (128.5 μL, 923.4 μmol) and 4-methylindoline (90.1 mg, 677.1 μmol) were added. The mixture was stirred at 15 °C under N2 atmosphere for 5 h. The reaction mixture was diluted with H2O (60 mL) and extracted with DCM (200 mL x 2). The combined organic layers were washed with saturated brine (80 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate = 10:1 to 1:1). Example 1, 5-(4-methylindolin-1-yl)sulfonyl-2H-isoquinolin-1-one (90 mg, 252 μmol, 41.1% yield) was obtained as a white solid. LC-MS: [M+1] 340.09.

[0095] 1H NMR(400MHz,DMSO-d6):δ 11.65(br,1H),8.48(d,J=8Hz,1H),8.26(d,J=7.6Hz,HI),7.59(t,J=7.6Hz,1H),7.34(t,J=6Hz,1H ),7.20~7.02(m,3H),6.81(d,J=7.6Hz,1H),4.04(t,J=8.0Hz,2H),2.89(t,J=8Hz,2H),2.11(s,3H). [ka] Compound 2-2: To a solution of 1-chloroisoquinoline-5-sulfonyl chloride (0.4 g, 1.53 mmol) in DCM (10 mL), TEA (318 μL, 2.29 mmol) and indolin-5-ol (226.9 mg, 1.68 mmol) were added. The mixture was stirred at 25 °C under N2 atmosphere for 12 h. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether: ethyl acetate = 10:1 to 1:1). Compound 2-2, 1-[(1-chloro-5-isoquinolyl)sulfonyl]indolin-5-ol (350 mg, 970.0 μmol, 63.6% yield) was obtained as a yellow solid.

[0096] Example 2: A solution of 1-[(1-chloro-5-isoquinolyl)sulfonyl]indolin-5-ol (330 mg, 914.6 μmol) in HCl (10 mL, 9N) was stirred at 90° C. for 12 h under N2 atmosphere. The reaction mixture was quenched by adding saturated NaHCO3 solution until pH=7, then diluted with H2O (30 mL) and extracted with EtOAc (10 mL×3). The combined organic layers were washed with saturated brine (30 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Waters Xbridge Prep OBDC18 150 mm×40 mm×10 μm; mobile phase: [A, water (10 mM NH4HCO3)-B, ACN]; B%: 25%-55%, 11 min). Example 2, 5-(5-hydroxyindolin-1-yl)sulfonyl-2H-isoquinolin-1-one (6 mg, 17.1 μmol, 1.87% yield) was obtained as a yellow solid. LC-MS: [M+1] 342.07.

[0097] 1 H NMR (400 MHz, CDCl3): δ 10.16 (br, 1H), 8.73 (d, J = 8 Hz, 1H), 8.20 (d, J = 8.8 Hz, 1H), 7.56-7.44 (m, 2H), 7.38-7.30 (m, 1H), 6.74 (s, 1H), 6.43 (d, J = 6.4 Hz, 1H), 6.35 (d, J = 8.4 Hz, 1H), 3.54 (t, J = 8.4 Hz, 2H), 2.93 (d, J = 8.4 Hz, 2H). One proton was exchanged. [ka]

[0098] Compound 3-1: To a solution of 1-chloroisoquinoline-5-sulfonyl chloride (0.3 g, 1.14 mmol) in DCM (8 mL) was added TEA (238.9 μL, 1.72 mmol) and indoline (109.1 mg, 915.6 μmol). The mixture was stirred at 15 °C under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (60 mL) and extracted with EtOAc (100 mL × 3). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The crude product, compound 3-1, 1-chloro-5-indolin-1-ylsulfonyl-isoquinoline (0.2 g, crude), was obtained as a yellow solid. Compound 3-1 was used in the next step without further purification.

[0099] Example 3: A mixture of 1-chloro-5-indolin-1-ylsulfonyl-isoquinoline (0.2 g, 580.02 μmol, 1 equiv) in aqueous HCl (5 mL, 12 M) was stirred at 100° C. for 12 h under N2 atmosphere. The reaction mixture was quenched by adding ice water (15 mL) at 0° C., then NaHCO3 was added to the mixture to adjust pH to 8 and filtered. The filtrate was concentrated under reduced pressure to give a residue. The residue was partitioned between H2O (60 mL) and DCM (100 mL×3). The combined organic layer was washed with saturated brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate=10:1 to 0:1). Example 3, 5-indolin-1-ylsulfonyl-2H-isoquinolin-1-one (40 mg, 117.5 μmol, 20.2% yield) was obtained as a white solid. LC-MS: [M+1] 326.07.

[0100] 1H NMR (400 MHz, MeOD): δ 8.58 (d, J = 8.4 Hz, 1H), 8.34 (d, J = 8 Hz, 1H), 7.61 (t, J = 8 Hz, 1H), 7.47 (d, J = 8 Hz, 1H), 7.38 (d, J = 7.6 Hz, 1H), 7.25-7.10 (m, 3H), 7.00 (t, J = 8 Hz, 1H), 4.03 (t, J = 8 Hz, 2H), 2.85 (t, J = 8.4 Hz, 2H). One proton was exchanged. [ka]

[0101] Example 4: To a solution of 1-hydroxyisoquinoline-5-sulfonyl chloride (100.0 mg, 410.4 μmol) in DCM (5 mL) was added TEA (85.7 μL, 615.6 μmol) and 6-chloroindoline (56.7 mg, 369.4 μmol). The mixture was stirred at 15 °C under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (50 mL) and extracted with DCM (150 mL x 2). The combined organic layers were washed with saturated brine (100 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether (Pether):Ethyl acetate = 8:1 to 0:1). 40 mg of Example 4, 5-(6-chloroindolin-1-yl)sulfonyl-2H-isoquinolin-1-one, was obtained as a white solid. LC-MS: [M+1] 360.03.

[0102] 1 H NMR (400 MHz, MeOD): δ 8.60 (d, J = 8 Hz, 1H), 8.35 (d, J = 8 Hz, 1H), 7.63 (t, J = 8 Hz, 1H), 7.45 (d, J = 2 Hz, 1H), 7.37 (d, J = 7.6 Hz, 1H), 7.26 (d, J = 7.6 Hz, 1H), 7.10 (d, J = 7.6 Hz, 1H), 7.02-6.96 (m, 1H), 4.03 (t, J = 8.4 Hz, 2H), 2.87 (t, J = 8.4 Hz, 2H). One proton was exchanged. [ka]

[0103] Example 5: To a solution of 1-hydroxyisoquinoline-5-sulfonyl chloride (150.0 mg, 615.6 μmol) in DCM (5 mL) was added 6-fluoroindoline (75.9 mg, 554.0 μmol) and TEA (128.5 μL, 923.3 μmol). The mixture was stirred at 15 °C under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (30 mL) and extracted with DCM (100 mL x 2). The combined organic layer was washed with saturated brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate = 10:1 to 0:1). Example 5, 5-(6-fluoroindolin-1-yl)sulfonyl-2H-isoquinolin-1-one (80 mg, 204.3 μmol, 33.2% yield) was obtained as a yellow solid. LC-MS: [M+1] 344.06.

[0104] 1 H NMR (400 MHz, MeOD): δ 8.59 (d, J = 8.0 Hz, 1H), 8.36 (d, J = 7.6 Hz, 1H), 7.62 (t, J = 8 Hz, 1H), 7.38 (d, J = 8 Hz, 1H), 7.26 (d, J = 7.6 Hz, 1H), 7.22-7.17 (m, 1H), 7.12-7.06 (m, 1H), 6.75-6.66 (m, 1H), 4.03 (t, J = 8.4 Hz, 2H), 2.87 (t, J = 8.4 Hz, 2H). One proton was exchanged. [ka]

[0105] Compound 6-1: To a solution of 1-chloroisoquinoline-5-sulfonyl chloride (0.3 g, 1.14 mmol) in DCM (8 mL) was added TEA (239 μL, 1.72 mmol) and 6-methylindoline (121 mg, 916 μmol). The mixture was stirred at 15 °C under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (60 mL) and extracted with EtOAc (100 mL × 3). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The crude product, compound 6-1, 1-chloro-5-(6-methylindolin-1-yl)sulfonyl-isoquinoline (0.2 g, crude) was obtained as a yellow solid. The crude product was used in the next step without further purification.

[0106] Example 6: A mixture of 1-chloro-5-(6-methylindolin-1-yl)sulfonyl-isoquinoline (0.2 g, 557 μmol) in aqueous HCl (5 mL, 12 M) was degassed and purged with N2 three times, then the mixture was stirred at 100 °C under N2 atmosphere for 12 h. The reaction mixture was quenched by adding ice water (15 mL) at 0 °C, then NaHCO3 was added to the mixture to adjust pH to 8 and filtered. The filtrate was concentrated under reduced pressure to give a residue. The reaction mixture was diluted with H2O (60 mL) and extracted with DCM (100 mL x 3). The combined organic layer was washed with saturated brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate = 10:1 to 0:1). Example 6, 5-(6-methylindolin-1-yl)sulfonyl-2H-isoquinolin-1-one (40 mg, 107.4 μmol, 19.2% yield) was obtained as a white solid. LC-MS: [M+1] 340.09.

[0107] 1H NMR (400 MHz, MeOD): δ 8.57 (d, J = 8.4 Hz, 1H), 8.32 (d, J = 7.6 Hz, 1H), 7.59 (t, J = 8 Hz, 1H), 7.38 (d, J = 8 Hz, 1H), 7.30 (s, 1H), 7.22 (d, J = 8 Hz, 1H), 6.99 (d, J = 7.6 Hz, 1H), 6.82 (d, J = 7.6 Hz, 1H), 4.01 (t, J = 8 Hz 2H), 2.79 (t, J = 8 Hz 2H), 2.31 (s, 3H). One proton was exchanged. [ka]

[0108] Example 7: To a solution of 1-oxo-2H-isoquinoline-5-sulfonyl chloride (0.3 g, 1.23 mmol) in DCM (10 mL) was added TEA (257.0 μL, 1.85 mmol) and indolin-4-ylmethanol (202.0 mg, 1.35 mmol). The mixture was stirred at 25 °C under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (15 mL) and extracted with DCM (5 mL × 3). The combined organic layer was washed with saturated brine (15 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether: ethyl acetate = 1:0 to 0:1). Example 7, 5-[4-(hydroxymethyl)indolin-1-yl]sulfonyl-2H-isoquinolin-1-one (35 mg, 91.59 μmol, 7.44% yield) was obtained as a dark brown solid. LC-MS: [M+1] 356.08.

[0109] 1 H NMR (400 MHz, MeOD): δ 8.56 (d, J = 8.0 Hz, 1H), 8.34 (d, J = 7.6 Hz, 1H), 7.58 (t, J = 7.6 Hz, 1H), 7.50 (d, J = 8 Hz, 2H), 7.22 (d, J = 8 Hz, 1H), 7.17 (t, J = 8 Hz, HI), 7.04 (d, J = 7.6 Hz, 1H), 4.46 (s, 2H), 4.06 (t, J = 8.4 Hz, 2H), 2.91 (t, J = 8.4 Hz, 2H). Two protons were exchanged. [ka] Example 8: To a solution of 1-hydroxyisoquinoline-5-sulfonyl chloride (150 mg, 615 μmol) in DCM (5 mL) was added TEA (128.5 μL, 923.3 μmol) and 4-(trifluoromethyl)indoline (103.6 mg, 554.0 μmol). The mixture was stirred at 15 °C under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (30 mL) and extracted with DCM (75 mL x 2). The combined organic layer was washed with saturated brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate = 10:1 to 0:1). Example 8, 5-[4-(trifluoromethyl)indolin-1-yl]sulfonyl-2H-isoquinolin-1-one (20 mg, 44.2 μmol, 7.18% yield) was obtained as a white solid. LC-MS: [M+1] 394.06.

[0110] 1 H NMR (400 MHz, MeOD): δ 8.60 (d, J = 8 Hz, 1H), 8.38 (d, J = 7.6 Hz, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.63 (t, J = 8 Hz, 1H), 7.40-7.20 (m, 4H), 4.10 (t, J = 8.4 Hz, 2H), 3.05 (t, J = 8.4 Hz, 2H). One proton was exchanged. [ka]

[0111] Example 9: To a solution of 1-hydroxyisoquinoline-5-sulfonyl chloride (150 mg, 615.5 μmol) in DCM (5 mL) was added TEA (128.5 μL, 923.3 μmol) and 4-cyclopropylindoline (88.2 mg, 554.0 μmol). The mixture was stirred at 15 °C under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (40 mL) and extracted with DCM (100 mL x 2). The combined organic layer was washed with saturated brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate = 10:1 to 0:1). Example 9, 5-(4-cyclopropylindolin-1-yl)sulfonyl-2H-isoquinolin-1-one (25 mg, 57.8 μmol, 9.39% yield) was obtained as a white solid. LC-MS: [M+1] 366.10.

[0112] 1 H NMR(400MHz,MeOD):δ 8.57(d,J=7.6Hz,1H),8.33(d,J=7.6Hz,1H),7.59(t,J=8Hz,1H),7.33(d,J=8Hz,1H),7.26(d,J=8Hz,1H),7.19(d,J=8Hz,1H),7.07(t,J= 7.6Hz,1H), 6.56(d,J=7.6Hz,1H),4.05(t,J=8.4Hz,1H),2.93(t,J=8.4Hz,2H),1.73~1.67(m,1H),0.88~0.86(m,2H),0.57~0.55(m,2H). [ka]

[0113] Compound 10-1: To a solution of 1-hydroxyisoquinoline-5-sulfonyl chloride (150 mg, 615.5 μmol) in DCM (5 mL), TEA (128.5 μL, 923.3 μmol) and 4-vinylindoline (98.3 mg, 677.1 μmol) were added. The mixture was stirred at 15 °C under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (20 mL) and extracted with DCM (80 mL × 2). The combined organic layer was washed with saturated brine (30 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether: ethyl acetate = 10: 1 to 0: 1). Compound 10-1, 5-(4-vinylindolin-1-yl)sulfonyl-2H-isoquinolin-1-one (50 mg, 141.8 μmol, 23.05% yield) was obtained as a yellow solid.

[0114] Example 10: A mixture of 5-(4-vinylindolin-1-yl)sulfonyl-2H-isoquinolin-1-one (50 mg, 141.8 μmol), Pd / C (5 mg, 10 wt%) in MeOH (5 mL) was degassed and purged with H2 three times, then the mixture was stirred under H2 atmosphere (15 psi) at 15°C for 12 h. The reaction mixture was filtered and the filter was concentrated. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate = 5:1 to 0:1). The residue was purified by preparative HPLC (column: Waters Xbridge 150 mm x 50 mm x 10 μm; mobile phase: [A, water (10 mM NH4HCO3)-B, ACN]; B%: 30% to 60%, 12 min). Example 10, 5-(4-ethylindolin-1-yl)sulfonyl-2H-isoquinolin-1-one (14 mg, 39.4 μmol, 27.7% yield) was obtained as a white solid. LC-MS: [M+1] 354.10.

[0115] 1H NMR (400 MHz, MeOD): δ 8.58 (d, J = 7.6 Hz, 1H), 8.34 (d, J = 7.6 Hz, 1H), 7.60 (t, J = 8 Hz, 1H), 7.32 (t, J = 7.2 Hz, 2H), 7.18 (d, J = 4.0 Hz, 1H), 7.13 (t, J = 7.6 Hz, 1H), 6.88 (d, J = 4 Hz, 1H), 4.03 (t, J = 8.4 Hz, 2H), 2.76 (t, J = 8.4 Hz, 2H), 2.50-2.44 (m, 2H), 1.06 (t, J = 7.6 Hz, 3H). One proton was exchanged. [ka]

[0116] Example 11: To a solution of 1-oxo-2H-isoquinoline-5-sulfonyl chloride (244.2 mg, 1.00 mmol) in DCM (5 mL) was added TEA (209.3 μL, 1.50 mmol) and 1-indolin-4-ylethanol (180 mg, 1.10 mmol). The mixture was stirred at 25 °C under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (60 mL) and extracted with DCM (150 mL x 2). The combined organic layer was washed with saturated brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate = 10:1 to 0:1). The residue was purified by preparative HPLC (column: Waters Xbridge 150 mm x 25 mm x 5 μm; mobile phase: [A, water (10 mM NH4HCO3)-B, ACN]; B%: 10%-40%, 10 min). Example 11, 5-[4-(1-hydroxyethyl)indolin-1-yl]sulfonyl-2H-isoquinolin-1-one (40 mg) was obtained as a white solid. LC-MS: [M+1] 370.10.

[0117] 1H NMR (400 MHz, MeOD): δ 8.57 (d, J = 7.6 Hz, 1H), 8.35 (d, J = 8 Hz, 1H), 7.59 (t, J = 8 Hz, 1H), 7.38 (d, J = 8, 1H), 7.34 (d, J = 8 Hz, 1H), 7.21-7.15 (m, 2H), 7.11 (d, J = 7.6 Hz, 1H), 4.88-4.71 (m, 1H), 4.07-4.01 (m, 2H), 2.89-2.80 (m, 2H), 1.26 (d, J = 6.4 Hz, 3H). Two protons were exchanged. [ka]

[0118] Compound 12-1: To a solution of 1-chloroisoquinoline-5-sulfonyl chloride (0.3 g, 1.14 mmol) in DCM (8 mL) was added TEA (238.9 μL, 1.72 mmol) and 3,3-dimethylindoline (134.8 mg, 915.6 μmol). The mixture was stirred at 15 °C under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (60 mL) and extracted with EtOAc (100 mL × 3). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The crude product, compound 12-1, 1-chloro-5-(3,3-dimethylindolin-1-yl)sulfonyl-isoquinoline (0.2 g, crude) was obtained as a yellow solid. The crude product was used in the next step without further purification.

[0119] Example 12: A mixture of 1-chloro-5-(3,3-dimethylindolin-1-yl)sulfonyl isoquinoline (0.2 g, 536.3 μmol) in aqueous HCl (5 mL, 12 M) was degassed and purged with N2 three times, then the mixture was stirred at 100 °C under N2 atmosphere for 12 h. The reaction mixture was quenched by adding ice water (15 mL) at 0 °C, then NaHCO3 was added to the mixture to adjust pH to 8, filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was diluted with H2O (60 mL) and extracted with DCM (100 mL x 3). The combined organic layer was washed with saturated brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate = 10:1 to 0:1). Example 12, 5-(3,3-dimethylindolin-1-yl)sulfonyl-2H-isoquinolin-1-one (12 mg, 31.5 μmol, 5.88% yield) was obtained as a white solid. LC-MS: [M+1] 354.10.

[0120] 1 H NMR (400 MHz, MeOD): δ 8.58, (d, J = 8 Hz, 1H), 8.42 (d, J = 8 Hz, 1H), 7.62 (t, J = 7.6 Hz, 1H), 7.48 (d, J = 8 Hz, 1H), 7.43 (d, J = 7.6 Hz, 1H), 7.23 (d, J = 7.6 Hz, 1H), 7.18 (t, J = 7.6 Hz, 1H), 7.11 (d, J = 7.6 Hz, 1H), 7.02 (t, J = 7.6 Hz, 1H), 3.73 (s, 2H), 1.08 (s, 6H). One proton was exchanged. [ka]

[0121] Example 13: To a solution of 1-hydroxyisoquinoline-5-sulfonyl chloride (100 mg, 410.4 μmol) in DCM (5 mL) was added TEA (85.6 μL, 615.6 μmol) and 3-methylindoline (55.7 mg, 328.3 μmol). The mixture was stirred at 15 °C under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (50 mL) and extracted with DCM (150 mL x 2). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether: ethyl acetate = 10:1 to 0:1). 70 mg of Example 13, 5-(3-methylindolin-1-yl)sulfonyl-2H-isoquinolin-1-one was obtained as a white solid. LC-MS: [M+1] 340.09.

[0122] 1 H NMR(400MHz,DMSO-d6):δ 11.67(s,1H),8.49(d,J=8Hz,1H),8.30(d,J=8Hz,1H),7.61(t,J=7.6Hz,1H),7.31~7.30(m,2H),7.20~7.13(m, 3H), 7.01(t,J=7.6Hz,1H),4.19(t,J=9.2Hz,1H),3.57-3.53(m,1H),3.29~3.24(m,1H),1.05(d,J=6.8Hz,3H). [ka]

[0123] Compound 14-1: To a solution of 1-hydroxyisoquinoline-5-sulfonyl chloride (83.4 mg, 342.6 μmol) in DCM (5 mL), TEA (71.5 μL, 513.8 μmol) and 4-isopropenylindoline (60 mg, 376.82 μmol) were added. The mixture was stirred at 15 °C under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (10 mL) and extracted with DCM (50 mL × 3). The combined organic layer was washed with saturated brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether: ethyl acetate = 10: 1 to 1: 1). Compound 14-1,5-(4-isopropenylindolin-1-yl)sulfonyl-2H-isoquinolin-1-one (50 mg, 136.4 μmol, 39.8% yield) was obtained as a yellow solid.

[0124] Example 14: To a solution of 5-(4-isopropenylindolin-1-yl)sulfonyl-2H-isoquinolin-1-one (50 mg, 136.45 μmol, 1 equiv.) in MeOH (5 mL), Pd / C (5 mg, 10% purity) was added under H2. The mixture was stirred at 15° C. for 12 h at 15 psi pressure. The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate=5:1 to 0:1). The residue was purified by preparative HPLC (column: Waters Xbridge 150 mm×50 mm×10 μm; mobile phase: [A, water (10 mM NH4HCO3)-B, ACN]; B%: 30% to 60%, 12 min). Example 14, 5-(4-isopropylindolin-1-yl)sulfonyl-2H-isoquinolin-1-one (8 mg, 21.50 μmol, 15.7% yield) was obtained as a white solid. LC-MS: [M+1] 368.12.

[0125] 1H NMR (400 MHz, MeOD): δ 8.57 (d, J = 8.0 Hz, 1H), 8.34 (d, J = 6.8 Hz, 1H), 7.59 (t, J = 8 Hz, 1H), 7.32-7.26 (m, 2H), 7.15 (t, J = 7.6 Hz, 2H), 6.95 (d, J = 7.6 Hz, 1H), 4.00 (t, J = 8 Hz, 2H), 2.81-2.71 (m, 3H), 1.10 (d, J = 6.8 Hz, 6H). One proton was exchanged. [ka]

[0126] Example 15: To a solution of 1-hydroxyisoquinoline-5-sulfonyl chloride (202.8 mg, 832.3 μmol) in DCM (5 mL) was added TEA (173.8 μL, 1.25 mmol) and indoline-6-carbonitrile (120 mg, 832.3 μmol). The mixture was stirred at 25 °C under N2 atmosphere for 5 h. The reaction mixture was quenched by adding H2O (40 mL), and then the reaction mixture was extracted with DCM (100 mL x 2). The combined organic layer was washed with saturated brine 50 (mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether: ethyl acetate = 10: 1 to 0: 1). Example 15, 1-[(1-oxo-2H-isoquinolin-5-yl)sulfonyl]indoline-6-carbonitrile (80 mg, 215.8 μmol, 25.9% yield) was obtained as a yellow solid. LC-MS: [M+1] 351.07.

[0127] 1 H NMR(400MHz,DMSO-d6):δ 11.68(s,1H),8.51(d,J=7.6Hz,1H),8.37(d,J=6.4Hz,1H),7.64(t,J=8Hz,1H),7.58(s, 1H),7.47-7.40(m,3H),7.11(d,J=7.2Hz,1H),4.06(t,J=8Hz,2H),3.07(t,J=8.0Hz,2H). [ka]

[0128] Example 16: To a solution of 1-oxo-2H-isoquinoline-5-sulfonyl chloride (176.6 mg, 725.1 μmol) in DCM (3 mL) was added TEA (151.3 μL, 1.09 mmol) and 4,6-dichloroindoline (150 mg, 797.6 μmol). The mixture was stirred at 25 °C under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (60 mL) and extracted with DCM (150 mL x 2). The combined organic layer was washed with saturated brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate = 10:1 to 0:1). The residue was purified by preparative HPLC (column: Waters Xbridge Prep OBD C18 150 mm x 40 mm x 10 μm; mobile phase: [A, water (10 mM NH4HCO3)-B, ACN]; B%: 35%-55%, 11 min). Example 16, 5-(4,6-dichloroindolin-1-yl)sulfonylisoquinolin-1-ol (60 mg, 150.5 μmol, 20.7% yield) was obtained as a white solid. LC-MS: [M+1] 393.99.

[0129] 1 H NMR(400MHz,DMSO-d6):δ 8.53(d,J=7.6Hz,1H),8.31(d,J=8Hz,2H),7.67(t,J=8Hz,1H),7.39(d,J=7.6Hz,1H)7. 23(d,J=8.8Hz,2H),7.10(d,J=7.6Hz,1H),4.09(t,J=8.4Hz,2H),3.03(t,J=8.4Hz,2H). [ka]

[0130] Example 17: To a solution of 1-oxo-2H-isoquinoline-5-sulfonyl chloride (50 mg, 205.2 μmol) in DCM (5 mL) was added TEA (85.6 μL, 615.6 μmol) and 4-cyclopropylindoline-6-carbonitrile (37.8 mg, 205.2 μmol). The mixture was stirred at 25° C. under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (15 mL) and extracted with DCM (80 mL×2). The combined organic layer was washed with saturated brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Xtimate C18 150 mm x 25 mm x 5 μm; mobile phase: [A, water (10 mM NH4HCO3)-B, ACN]; B%: 50%-80%, 10 min). Example 17, 4-cyclopropyl-1-[(1-hydroxy-5-isoquinolyl)sulfonyl]indoline-6-carbonitrile (19 mg, 47.5 μmol, 23.1% yield) was obtained as a yellow solid. LC-MS: [M+1] 391.10.

[0131] 1 H NMR (400 MHz, MeOD): δ 8.62 (d, J = 8 Hz, 1H), 8.39 (d, J = 6.8 Hz, 1H), 7.65 (t, J = 7.8 Hz, 1H), 7.54 (s, 1H), 7.35 (d, J = 7.6 Hz, 1H), 7.27 (d, J = 7.6 Hz, 1H), 6.92 (s, 1H), 4.09 (t, J = 8.4 Hz, 2H), 3.07 (t, J = 8.4 Hz, 2H), 1.79-1.77 (m, 1H), 0.98-0.95 (m, 2H), 0.68-0.66 (m, 2H). One proton was exchanged. [ka]

[0132] Example 18: To a solution of 1-oxo-2H-isoquinoline-5-sulfonyl chloride (100 mg, 410.4 μmol) in DCM (5 mL), TEA (65.9 μL, 474.0 μmol) and 4-methylindoline-6-carbonitrile (50 mg, 316.0 μmol) were added. The reaction mixture was stirred at 25 °C under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (20 mL) and extracted with DCM (100 mL x 2). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate = 1:0 to 0:1). The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate = 1:0 to 4:5). Example 18, 1-[(1-hydroxy-5-isoquinolyl)sulfonyl]-4-methylindoline-6-carbonitrile (8 mg, 19.9 μmol, 6.30% yield) was obtained as a white solid. LC-MS: [M+1] 365.08.

[0133] 1 H NMR (400 MHz, MeOD): δ 8.61 (d, J = 8 Hz, 1H), 8.38 (d, J = 8 Hz, 1H), 7.64 (t, J = 8 Hz, 1H), 7.56 (s, 1H), 7.37 (d, J = 7.6 Hz, 1H), 7.28 (d, J = 8 Hz, 1H), 7.21 (s, 1H), 4.07 (t, J = 8.4 Hz, 2H), 2.96 (t, J = 8.4 Hz, 2H), 2.20 (s, 3H). One proton was exchanged. [ka]

[0134] Compound 19-2: A mixture of 3,5-dichlorobenzaldehyde (25 g, 142.8 mmol), 2,2-diethoxyethanamine (83.08 mL, 571.3 mmol) in toluene (200 mL) was degassed and purged with N2 three times, then the mixture was stirred at 110 °C under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (500 mL) and extracted with EtOAc (900 mL x 2). The combined organic layers were washed with saturated brine (200 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The crude product, compound 19-2, (E)-1-(3,5-dichlorophenyl)-N-(2,2-diethoxyethyl)methanimine (35 g, crude) was obtained as a yellow solid. The crude product was used in the next step without further purification.

[0135] Compound 19-3: To a solution of H2SO4 (500 mL), (E)-1-(3,5-dichlorophenyl)-N-(2,2-diethoxyethyl)methanimine (30 g, 103.3 mmol) in DCM (100 mL) was added dropwise at 125 °C. The resulting mixture was stirred at 125 °C for 6 h under N2 atmosphere. The reaction mixture was quenched by adding ice water (200 mL) at 0 °C, and then aqueous NaOH (200 mL) was added to the mixture to adjust pH to 8. It was extracted with EtOAc (1000 mL x 2). The combined organic layer was washed with saturated brine (200 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate = 20:1 to 5:1). Compound 19-3, 5,7-dichloroisoquinoline (8 g, 40.3 mmol, 39.0% yield) was obtained as a yellow solid.

[0136] Compound 19-4: A mixture of 5,7-dichloroisoquinoline (100 mg, 504.9 μmol), diphenylmethanimine (137.2 mg, 757.3 μmol), (5-diphenylphosphanyl-9,9-dimethyl-xanthen-4-yl)-diphenyl-phosphane, methanesulfonate, [2-[2-(methylamino)phenyl]phenyl]palladium (485.9 mg, 504.9 μmol), t-BuONa (2M, 1.26 mL) in toluene (10 mL) was degassed and purged with N 3 times, then the mixture was stirred at 100° C. under N 2 atmosphere for 12 h. The reaction mixture was diluted with H 2 O (20 mL) and extracted with DCM (80 mL×2). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate=20:1 to 1:1). Compound 19-4, N-(7-chloro-5-isoquinolyl)-1,1-diphenyl-methanimine (40 mg, 116.6 μmol, 11.5% yield), was obtained as a yellow solid.

[0137] Compound 19-5: To a solution of N-(7-chloro-5-isoquinolyl)-1,1-diphenyl-methanimine (0.3 g, 875.0 μmol) in THF (10 mL) was added HCl (3 M, 525.0 μL). The mixture was stirred at 25 °C for 2 h under N2 atmosphere. The reaction mixture was quenched by adding ice water (10 mL) at 0 °C, and then aqueous NaOH (10 mL) was added to the mixture to adjust pH to 8. The reaction mixture was diluted with H2O (10 mL) and extracted with DCM (50 mL x 2). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate = 5:1 to 1:1). Compound 19-5, 7-chloroisoquinolin-5-amine (0.1 g, 559.8 μmol, 63.9% yield) was obtained as a yellow solid.

[0138] Compound 19-6: To a solution of 7-chloroisoquinolin-5-amine (0.1 g, 559 μmol) in HCl (5 mL) was added NaNO2 (38.6 mg, 559.8 μmol) and H2O (1 mL) at -5 °C. The mixture was stirred at -5 °C for 1 h. It was then transferred in one portion to a solution of CuCl (13.8 mg, 139.9 μmol) in H2O (1 mL) in AcOH (5 mL), which was saturated with bubbling SO2. The mixture was stirred at 25 °C for 2 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was dissolved in water (20 mL) and DCM and extracted with DCM (80 mL x 2). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The crude product, compound 19-6, 7-chloroisoquinoline-5-sulfonyl chloride (0.2 g, crude), was obtained as a yellow solid, which was used in the next step without further purification.

[0139] Compound 19-7: To a solution of 7-chloroisoquinoline-5-sulfonyl chloride (0.2 g, 763.0 μmol) in acetone (10 mL), K2CO3 (158.1 mg, 1.14 mmol) and 6-chloroindoline (128.9 mg, 839.3 μmol) were added. The mixture was stirred at 25 °C under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (20 mL) and extracted with DCM (80 mL × 2). The combined organic layer was washed with saturated brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether: ethyl acetate = 1:0 to 1:1). Compound 19-7, 7-chloro-5-(6-chloroindolin-1-yl)sulfonyl-isoquinoline (80 mg, 210.9 μmol, 27.6% yield) was obtained as a yellow solid.

[0140] Compound 19-8: A mixture of 7-chloro-5-(6-chloroindolin-1-yl)sulfonyl-isoquinoline (80 mg, 210.9 μmol), m-CPBA (65.7 mg, 316.4 μmol) in DCM (5 mL) was cooled to 0 °C, and then the mixture was stirred at 25 °C under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (15 mL) and extracted with DCM (25 mL × 2). The combined organic layer was washed with 10 mL of saturated brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether: EtOAc = 10: 1 to DCM: MeOH = 10: 1). Compound 19-8, 7-chloro-5-(6-chloroindolin-1-yl)sulfonyl-2-oxide-isoquinolin-2-ium (50 mg, 126.5 μmol, 59.9% yield) was obtained as a yellow solid.

[0141] Compound 19-9: A mixture of 7-chloro-5-(6-chloroindolin-1-yl)sulfonyl-2-oxide-isoquinolin-2-ium (50 mg, 126.5 μmol) in ACO (3 mL) was warmed to 90° C., and then the mixture was stirred at 90° C. for 3 h under N2 atmosphere. The reaction mixture was concentrated under reduced pressure to give a residue. The crude product [7-chloro-5-(6-chloroindolin-1-yl)sulfonyl-1-isoquinolyl]acetate (40 mg, crude) was obtained as a brown solid, which was used in the next step without further purification.

[0142] Example 19: A mixture of [7-chloro-5-(6-chloroindolin-1-yl)sulfonyl-1-isoquinolyl]acetate (40 mg, 91.4 μmol) and KOH (7.70 mg, 137.2 μmol) in MeOH (5 mL) was degassed and purged with N2 three times, then the mixture was stirred at 25° C. under N2 atmosphere for 2 h. The mixture was then stirred at 70° C. under N2 atmosphere for 3 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Xtimate C18 150 mm×25 mm×5 μm; mobile phase: [A, water (10 mM NH4HCO3)-B, ACN]; B%: 50%-70%, 10 min). Example 19, 7-chloro-5-(6-chloroindolin-1-yl)sulfonyl-2H-isoquinolin-1-one (18 mg, 45.0 μmol, 49.2% yield) was obtained as a yellow solid. LC-MS: [M+1] 393.99.

[0143] 1 H NMR (400 MHz, DMSO-d6): δ 8.43 (d, J = 4.4 Hz, 1H), 8.21 (d, J = 2.8 Hz, 1H), 7.38 (d, J = 7.6 Hz, 1H), 7.33 (d, J = 1.6 Hz, 1H), 7.23 (d, J = 8 Hz, 1H), 7.08 (t, J = 7.6 Hz, 2H), 4.05 (t, J = 8.4 Hz, 2H), 2.95 (t, J = 8.4 Hz, 2H). One proton was exchanged. [ka]

[0144] Compound 20-1: To a solution of 7-chloroisoquinoline-5-sulfonyl chloride (0.1 g, 381.5 μmol) in acetone (8 mL), K2CO3 (79.0 mg, 572.2 μmol) and indoline-6-carbonitrile (60.5 mg, 419.6 μmol) were added. The mixture was stirred at 25 °C under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (20 mL) and extracted with DCM (80 mL × 2). The combined organic layer was washed with saturated brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether: ethyl acetate = 10: 1 to 0: 1). Compound 20-1, 1-[(7-chloro-5-isoquinolyl)sulfonyl]indoline-6-carbonitrile (30 mg, 81.1 μmol, 21.2% yield) was obtained as a yellow solid.

[0145] Compound 20-2: A mixture of 1-[(7-chloro-5-isoquinolyl)sulfonyl]indoline-6-carbonitrile (30 mg, 81.1 μmol), m-CPBA (26.2 mg, 121.6 μmol) in DCM (5 mL) was degassed and purged with N2 three times, then the mixture was stirred at 25 °C under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (15 mL) and extracted with DCM (50 mL x 2). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate = 5:1 to DCM:MeOH = 10:1). Compound 20-2, 1-(7-chloro-2-oxide-isoquinolin-2-ium-5-yl)sulfonylindoline-6-carbonitrile (30 mg), was obtained as a yellow solid.

[0146] Compound 20-3: A mixture of 1-(7-chloro-2-oxido-isoquinolin-2-ium-5-yl)sulfonylindoline-6-carbonitrile (30 mg, 77.7 μmol) in AcO (3 mL) was degassed and purged with N three times, then the mixture was stirred at 100° C. under N atmosphere for 12 h. The reaction mixture was concentrated under reduced pressure to give a residue. The crude product, compound 20-3, [7-chloro-5-(6-cyanoindolin-1-yl)sulfonyl-1-isoquinolyl]acetate (20 mg, crude), was obtained as a yellow oil, which was used in the next step without further purification.

[0147] Example 20: A mixture of [7-chloro-5-(6-cyanoindolin-1-yl)sulfonyl-1-isoquinolyl]acetate (20 mg, 46.7 μmol) and KOH (5.25 mg, 93.4 μmol) in MeOH (5 mL) was degassed and purged with N2 three times, then the mixture was stirred under N2 atmosphere at 25° C. for 2 h. The reaction mixture was diluted with H2O (10 mL) and extracted with DCM (50 mL×2). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: HUAPU C8 Extreme BDS 150 mm×30 mm×5 μm; mobile phase: [A, water (10 mM NH4HCO3)-B, ACN]; B%: 45%-55%, 10 min). Example 20, 1-[(7-chloro-1-oxo-2H-isoquinolin-5-yl)sulfonyl]indoline-6-carbonitrile (2 mg, 4.7 μmol, 10.2% yield) was obtained as a white solid. LC-MS: [M+1] 385.03.

[0148] 1H NMR (400 MHz, DMSO-d6): δ 8.44 (d, J = 2.4 Hz, 1H), 8.32 (d, J = 2 Hz, 1H), 7.68 (s, 1H), 7.52 (d, J = 1.2 Hz, 1H), 7.45-7.36 (m, 2H), 7.04 (d, J = 8.8 Hz, 1H), 4.07 (t, J = 8.4 Hz, 2H), 3.07 (t, J = 8.4 Hz, 2H). One proton was exchanged. [ka]

[0149] Compound 21-2: To a solution of n-BuLi (2.5M, 201.8 mL) in THF (100 mL) was added a solution of 4-bromoisoquinoline (30 g, 144.1 mmol) in THF (100 mL) at -65 °C. The mixture was stirred at -65 °C for 30 min. A solution of N-(benzenesulfonyl)-N-fluoro-benzenesulfonamide (100.0 g, 317.2 mmol) in THF (100 mL) was added at -65 °C. The mixture was stirred at -65 °C for 1 h. Then the mixture was stirred at 25 °C under N2 atmosphere for 10.5 h. The reaction mixture was diluted with H2O (500 mL) and extracted with EtOAc (1500 mL x 2). The combined organic layers were washed with saturated brine (100 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The crude product, compound 21-2, 4-fluoroisoquinoline (30 g, crude), was obtained as a brown oil, which was used in the next step without further purification.

[0150] Compound 21-3: To a solution of 4-fluoroisoquinoline (8 g, 54.3 mmol) in H2SO4 (50 mL) was added KNO3 (6.05 g, 59.8 mmol). The mixture was stirred at 25 °C for 12 h under N2 atmosphere. The reaction mixture was quenched by adding ice water (100 mL) at -15 °C, then aqueous NaOH (50 mL) was added to the mixture to adjust pH to 8. It was filtered, and the filtrate was concentrated under reduced pressure to obtain a residue. The residue was purified by column chromatography (SiO2, petroleum ether: ethyl acetate = 10: 1 to 1: 1). Compound 21-3, 4-fluoro-5-nitro-isoquinoline (5 g, 26.0 mmol, 47.8% yield) was obtained as a yellow solid.

[0151] Compound 21-4: A mixture of 4-fluoro-5-nitro-isoquinoline (5 g, 26.0 mmol), NH4Cl (11.1 g, 208.1 mmol), Zn (13.6 g, 208.1 mmol), and HO (10 mL) in THF (20 mL) was degassed and purged with N2 three times, then the mixture was stirred at 25 °C under N2 atmosphere for 5 h. The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate = 10:1 to 1:1). Compound 21-4, 4-fluoroisoquinolin-5-amine (3 g, 18.5 mmol, 71.1% yield) was obtained as a yellow solid.

[0152] Compound 21-5: To a solution of 4-fluoroisoquinoline-5-amine (3 g, 18.5 mmol) in HCl (10 mL) was added NaNO3 (1.57 g, 18.5 mmol) and H2O (2 mL) at -15 °C. The mixture was stirred at -15 °C for 1 h under N2 atmosphere. It was then transferred to a solution of CuCl (457.8 mg, 4.62 mmol) and H2O (2 mL) in AcOH (10 mL), which was saturated with bubbling SO2. The mixture was stirred at -5 °C for 2 h. The reaction mixture was concentrated under reduced pressure to give a residue. The crude product, compound 21-5, 4-fluoroisoquinoline-5-sulfonyl chloride (1.1 g, crude), was obtained as a yellow solid, which was used in the next step without further purification.

[0153] Compound 21-6: A mixture of 4-fluoroisoquinoline-5-sulfonyl chloride (0.5 g, 2.04 mmol), 6-chloroindoline (250.1 mg, 1.63 mmol), TEA (424.9 μL, 3.05 mmol) in DCM (10 mL) was degassed and purged with N 3 times, then the mixture was stirred at 25 °C under N atmosphere for 12 h. The reaction mixture was diluted with H 2 O (30 mL) and extracted with DCM (100 mL × 2). The combined organic layer was washed with saturated brine (20 mL), dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO 2 , petroleum ether: ethyl acetate = 10: 1 to 1: 1). Compound 21-6, 5-(6-chloroindolin-1-yl)sulfonyl-4-fluoro-isoquinoline (0.2 g, 551.2 μmol) was obtained as a yellow solid.

[0154] Compound 21-7: A mixture of 5-(6-chloroindolin-1-yl)sulfonyl-4-fluoro-isoquinoline (0.2 g, 551 μmol), m-CPBA (142.6 mg, 826.9 μmol) in DCM (10 mL) was degassed and purged with N2 three times and stirred under N2 atmosphere at 25 °C for 12 h. The reaction mixture was diluted with H2O (20 mL) and extracted with DCM (100 mL x 2). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate = 5:1 to DCM:MeOH = 10:1). Compound 21-7, 5-(6-chloroindolin-1-yl)sulfonyl-4-fluoro-2-oxide-isoquinolin-2-ium (70 mg, 184 μmol, 33.5% yield) was obtained as a white solid.

[0155] Example 21: A mixture of 5-(6-chloroindolin-1-yl)sulfonyl-4-fluoro-2-oxide-isoquinolin-2-ium (70 mg, 184.7 μmol) in Ac2O (10 mL) was degassed and purged with N2 three times, then the mixture was stirred at 110° C. under N2 atmosphere for 8 h. The reaction mixture was diluted with H2O (20 mL) and extracted with DCM (80 mL×2). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate=10:1 to 0:1). The residue was purified by preparative HPLC (column: HUAPU C8 Extreme BDS 150 mm x 30 mm x 5 μm; mobile phase: [A, water (10 mM NH4HCO3)-B, ACN]; B%: 35%-55%, 10 min). Example 21, 5-(6-chloroindolin-1-yl)sulfonyl-4-fluoro-isoquinolin-1-ol (5 mg, 12.2 μmol, 6.61% yield) was obtained as a white solid. LC-MS: [M+1] 378.81.

[0156] 1H NMR (400 MHz, MeOD): δ 9.10 (s, HI), 8.74 (d, J = 7.6 Hz, 1H), 8.23 ​​(d, J = 7.6 Hz, 1H), 7.97 (d, J = 6.8 Hz, 1H), 7.81 (t, J = 7.6 Hz, 1H), 7.35 (d, J = 8 Hz, 1H), 7.12-7.15 (m, 1H), 4.16 (t, J = 8.8 Hz, 2H), 3.23 (t, J = 8.4 Hz, 2H). One proton was exchanged. [ka]

[0157] Compound 22-1: To a mixture of KNO3 (21.3 g, 211.4 mmol) in H2SO4 (600 mL) was added 4-bromoisoquinoline (40 g, 192.2 mmol) at 0° C., then the mixture was stirred at 25° C. under N2 atmosphere for 12 h. The reaction mixture was quenched by adding ice water (3000 mL), then NH3.H2O was added to the mixture to adjust pH to 8. The mixture was filtered and concentrated under reduced pressure to give a residue. The residue was washed with MeOH (500 mL) and then filtered. The solid was dissolved with EtOAc (500 mL) and H2O (1000 mL). The organic layer was concentrated under reduced pressure to give a residue. Compound 22-1, 4-bromo-5-nitro-isoquinoline (75 g, 296.3 mmol, 77.0% yield) was obtained as a yellow solid.

[0158] Compound 22-2: To a mixture of 4-bromo-5-nitro-isoquinoline (55 g, 217.3 mmol) in dioxane (500 mL) and H2O (50 mL), methylboronic acid (26.02 g, 434.6 mmol), Cs2CO3 (141.6 g, 434.6 mmol) and Pd(dppf)Cl2 (15.90 g, 21.73 mmol) were added in one portion. The mixture was heated to 110 °C and stirred for 12 h. The reaction mixture was filtered. The filtrate was diluted with H2O (1.2 L) and extracted with EtOAc (800 mL × 2). The combined organic layers were washed with brine (1.2 L), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate = 1:0 to 3:1). Compound 22-2, 4-methyl-5-nitro-isoquinoline (36 g, 191.3 mmol, 88.0% yield) was obtained as a yellow solid.

[0159] Compound 22-3: To a solution of 4-methyl-5-nitro-isoquinoline (33 g, 175.3 mmol) in THF (500 mL) and HO (250 mL), Zn (91.7 g, 1.40 mol) and NHCl (75.0 g, 1.40 mol) were added. The mixture was stirred at 25 °C for 12 h. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO, petroleum ether:ethyl acetate = 1:0 to 0:1). Compound 22-3, 4-methylisoquinolin-5-amine (20 g, 113.8 mmol, 64.8% yield) was obtained as a yellow solid.

[0160] Compound 22-4: Solution 1: To a mixture of 4-methylisoquinolin-5-amine (3 g, 18.9 mmol) in HCl (30 mL) was added NaNO2 (1.31 g, 18.9 mmol) and H2O (6 mL) in one portion under N2 at -5 °C. The mixture was stirred at -5 °C for 1 h. Solution 2: SO2 was bubbled into a solution of CuCl (469.3 mg, 4.74 mmol) in HOAc (30 mL) and H2O (6 mL) at 0 °C for 30 min. The two solutions were mixed and stirred at 25 °C for 1.5 h. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with H2O (300 mL) and extracted with DCM (200 mL x 3). The combined organic layers were washed with brine (300 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. Compound 22-4, 4-methylisoquinoline-5-sulfonyl chloride (2 g, crude) was obtained as a yellow solid and used directly without purification.

[0161] Compound 22-5: To a solution of 4-methylisoquinoline-5-sulfonyl chloride (2 g, 8.27 mmol) in acetone (30 mL), K2CO3 (3.43 g, 24.8 mmol) and indoline-6-carbonitrile (1.19 g, 8.27 mmol) were added. The mixture was stirred at 25 °C for 12 h. The mixture was heated to 50 °C and stirred for 2 h. The reaction mixture was diluted with H2O (200 mL) and extracted with DCM (200 mL × 2). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether: ethyl acetate = 1:0 to 0:1). Compound 22-5, 1-[(4-methyl-5-isoquinolyl)sulfonyl]indoline-6-carbonitrile (1.1 g, 2.52 mmol, 30.4% yield), was obtained as a yellow solid.

[0162] Compound 22-6: To a solution of 1-[(4-methyl-5-isoquinolyl)sulfonyl]indoline-6-carbonitrile (1.1 g, 3.15 mmol) in DCM (30 mL) was added m-CPBA (1.44 g, 6.93 mmol) at 0 °C. The mixture was warmed to 25 °C and stirred for 12 h. The reaction mixture was directly purified by column chromatography (SiO2, petroleum ether:ethyl acetate = 1:0, ethyl acetate:EtOH = 1:1). Compound 22-6, 1-(4-methyl-2-oxido-isoquinolin-2-ium-5-yl)sulfonylindoline-6-carbonitrile (1 g, 2.54 mmol, 80.7% yield) was obtained as a yellow solid.

[0163] Example 22: A mixture of 1-(4-methyl-2-oxido-isoquinolin-2-ium-5-yl)sulfonylindoline-6-carbonitrile (1 g, 2.74 mmol) in Ac2O (20 mL) was heated to 120° C. and stirred for 12 h. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was dissolved in DMF (20 mL) and filtered. The filtrate was purified by preparative HPLC (column: Waters Xbridge Prep OBD C18 150 mm×40 mm×10 μm; mobile phase: [A, water (10 mM NH4HCO3)-B, ACN]; B%: 20%-50%, 11 min) and concentrated. The product was added to EtOH (2 mL) and filtered to give 1-[(1-hydroxy-4-methyl-5-isoquinolyl)sulfonyl]indoline-6-carbonitrile (19 mg) as a pale yellow solid. LC-MS: [M+1] 365.08.

[0164] 1 H NMR(400MHz,DMSO-d6):δ 11.71(br,1H),8.59(d,J=6.4Hz,1H),7.89(d,J=6.4Hz,1H),7.59~7.51(m, 3H),7.25(s,2H),4.22(t,J=8.8Hz,2H),3.4(t,J=8.4Hz,2H),2.61(s,3H). [ka]

[0165] Compound 23-1: To a solution of 4-methylisoquinoline-5-sulfonyl chloride (100 mg, 413.7 μmol) in acetone (5 mL), K2CO3 (171.5 mg, 1.24 mmol) and 4-methylindoline-6-carbonitrile (52.36 mg, 331.0 μmol) were added. The mixture was stirred at 25 °C for 12 h. The mixture was heated to 50 °C and stirred for 6 h. The reaction mixture was diluted with H2O (100 mL) and extracted with DCM (100 mL × 2). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether: ethyl acetate = 1:0 to 0:1). Compound 23-1, 4-methyl-1-[(4-methyl-5-isoquinolyl)sulfonyl]indoline-6-carbonitrile (50 mg, crude) was obtained as a yellow solid.

[0166] Compound 23-2: To a solution of 4-methyl-1-[(4-methyl-5-isoquinolyl)sulfonyl]indoline-6-carbonitrile (50 mg, 137 μmol) in DCM (10 mL), m-CPBA (62.9 mg, 302.7 μmol) was added at 0° C. The mixture was heated to 25° C. and stirred for 2 h. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate=1:0, ethyl acetate:MeOH=5:1). Compound 23-2, 4-methyl-1-(4-methyl-2-oxide-isoquinolin-2-ium-5-yl)sulfonyl-indoline-6-carbonitrile (40 mg, crude) was obtained as a yellow solid.

[0167] Example 23: A mixture of 4-methyl-1-(4-methyl-2-oxide-isoquinolin-2-ium-5-yl)sulfonyl-indoline-6-carbonitrile (40 mg, 105.4 μmol) in Ac2O (5 mL) was heated to 100° C. and stirred for 12 h. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by preparative HPLC (column: Luna C18 100 mm×30 mm×5 μm; mobile phase: [A, water (0.1% TFA)-B, ACN]; B%: 30%-55%, 12 min). Example 23, 1-[(1-hydroxy-4-methyl-5-isoquinolyl)sulfonyl]-4-methyl-indoline-6-carbonitrile (1.6 mg, 3.97 μmol, 3.76% yield) was obtained as a brown solid. LC-MS: [M+1] 379.10. 1 H NMR (400 MHz, DMSO-d6): δ 11.71 (br, 1H), 8.59 (d, J=8 Hz, 1H), 7.88 (d, J=7.6 Hz, 1H), 7.53 (t, J=8 Hz, 1H), 7.39 (s, 1H), 7.26-7.25 (m, 1H), 7.09 (s, 1H), 4.22 (t, J=8 Hz, 2H) 2.61 (s, 6H) (2H may overlap with water peak). [ka]

[0168] Compound 24-1: To a solution of 4-methylisoquinoline-5-sulfonyl chloride (500 mg, 2.07 mmol) in acetone (10 mL), K2CO3 (857.7 mg, 6.21 mmol) and 6-chloroindoline (317.8 mg, 2.07 mmol) were added. The mixture was stirred at 25 °C for 12 h. The reaction mixture was filtered, and the filtrate was diluted with H2O (200 mL) and extracted with EtOAc (150 mL × 2). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether: ethyl acetate = 1:0 to 0:1). Compound 24-1, 5-(6-chloroindolin-1-yl)sulfonyl-4-methyl-isoquinoline (400 mg, 947.4 μmol, 45.80% yield) was obtained as a yellow solid.

[0169] Compound 24-2: To a solution of 5-(6-chloroindolin-1-yl)sulfonyl-4-methyl-isoquinoline (400 mg, 1.11 mmol) in DCM (10 mL) was added m-CPBA (579.3 mg, 2.79 mmol) at 0° C. The mixture was heated to 25° C. and stirred for 2.5 h. The reaction mixture was directly purified by column chromatography (SiO2, petroleum ether:ethyl acetate=1:0, ethyl acetate:MeOH=5:1). Compound 24-2, 5-(6-chloroindolin-1-yl)sulfonyl-4-methyl-2-oxide-isoquinolin-2-ium (300 mg, crude) was obtained as a yellow solid.

[0170] Example 24: A mixture of 5-(6-chloroindolin-1-yl)sulfonyl-4-methyl-2-oxide-isoquinolin-2-ium (300 mg, 800.3 μmol) in Ac2O (10 mL) was heated to 100° C. and stirred for 12 h. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by preparative HPLC (column: Waters Xbridge Prep OBD C18 150 mm×40 mm×10 μm; mobile phase: [A, water (10 mM NH4HCO3)-B, ACN]; B%: 30%-55%, 11 min). MeOH (2 mL) was added, the mixture was filtered and concentrated under reduced pressure to give compound 24, 5-(6-chloroindolin-1-yl)sulfonyl-4-methyl-isoquinolin-1-ol (6 mg, 15.2 μmol, 40.7% yield) as a yellow solid. LC-MS: [M+1] 374.05.

[0171] 1 H NMR (400 MHz, DMSO-d6): δ 11.70 (br, 1H), 8.59 (d, J = 4.4 Hz, 1H), 7.86 (d, J = 7.2 Hz, 1H), 7.54 (t, J = 7.6 Hz, 1H), 7.37 (d, J = 8 Hz, 1H), 7.25 (d, J = 4.8 Hz 1H), 7.09 (d, J = 8.8 Hz, 1H), 6.98 (s, 1H), 4.2 (t, J = 8 Hz, 1H), 3.26 (m, 2H, overlapped with solvent peak), 2.61 (s, 3H). One proton was exchanged. [ka]

[0172] Compound 25-2: A mixture of 4-nitroisoindoline-1,3-dione (25 g, 130.1 mmol), NaBH4 (11.13 g, 294.0 mmol) in MeOH (250 mL) was degassed and purged with N2 three times. The mixture was stirred at 25 °C under N2 atmosphere for 2 h. The solution was acidified with 20% HCl (100 mL) and the reaction mixture was concentrated under reduced pressure to give a residue. The dried residue was treated with acetone. The residue was purified by column chromatography (SiO2, petroleum ether: ethyl acetate = 10:1 to 0:1). Compound 25-2, 3-hydroxy-4-nitro-isoindolin-1-one (15 g, 59% yield) was obtained as a yellow solid.

[0173] Compound 25-3: A mixture of 3-hydroxy-4-nitro-isoindolin-1-one (10 g, 51.5 mmol) in HCl (70 mL, 20% aqueous solution) was degassed and purged with N2 three times. The mixture was stirred at 90 °C under N2 atmosphere for 12 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate = 10:1 to 1:1). Compound 25-3, 3-hydroxy-4-nitro-3H-isobenzofuran-1-one (10 g, crude), was obtained as a yellow solid and used without further purification.

[0174] Compound 25-4: A mixture of 3-hydroxy-4-nitro-3H-isobenzofuran-1-one (10 g, 51.2 mmol), N2H4.H2O (9.05 g, 153.7 mmol) in EtOH (200 mL) was degassed and purged with N2 three times. The mixture was stirred at 80 °C under N2 atmosphere for 5 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate to DCM:MeOH = 10:1 to 10:1). Compound 25-4, 5-nitro-2H-phthalazin-1-one (6 g, 31.3 mmol, 61.2% yield) was obtained as a yellow solid.

[0175] Compound 25-5: A mixture of 5-nitro-2H-phthalazin-1-one (6 g, 31.3 mmol), Pd / C (3 g, 10 wt%) in MeOH (100 mL) was degassed and purged with H 3 times, then the mixture was stirred at 25° C. for 12 h under H 2 atmosphere at 15 psi pressure. The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by column chromatography (SiO 2 , petroleum ether:ethyl acetate to DCM:MeOH=10:1 to 10:1). Compound 25-5, 5-amino-2H-phthalazin-1-one (3 g, 18.6 mmol, 59.3% yield) was obtained as a yellow solid.

[0176] Compound 25-6: To a solution of 5-amino-2H-phthalazin-1-one (3 g, 18.61 mmol) in HCl (20 mL) was added NaNO2 (1.28 g, 18.61 mmol) and H2O (5 mL) at -5 °C. The mixture was stirred at -5 °C for 1 h. It was then transferred in one portion to a solution of CuCl (460.7 mg, 4.65 mmol) and H2O (5 mL) in AcOH (15 mL), which was saturated by bubbling SO2 through it. The mixture was stirred at 25 °C under N2 atmosphere for 2 h. The reaction mixture was concentrated under reduced pressure to give a residue. The crude product of compound 25-6, 1-oxo-2H-phthalazine-5-sulfonyl chloride (1.5 g, 6.13 mmol, 32.9% yield), was obtained as a yellow solid and used in the next step without further purification.

[0177] Example 25: To a solution of 1-oxo-2H-phthalazine-5-sulfonyl chloride (1 g, 4.09 mmol) in DCM (15 mL) was added TEA (853.3 μL, 6.13 mmol) and 6-chloroindoline (502.2 mg, 3.27 mmol). The mixture was stirred at 25 °C under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (50 mL) and extracted with DCM (150 mL x 2). The combined organic layer was washed with saturated brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether: ethyl acetate = 10: 1 to 0: 1). Compound 25, 5-(6-chloroindolin-1-yl)sulfonyl-2H-phthalazin-1-one (0.15 g, 373.3 μmol, 9.13% yield) was obtained as a yellow solid. LC-MS: [M+1] 361.03.

[0178] 1 H NMR(400MHz,DMSO-d6):δ 13.08(s,1H),8.78(s,1H),8.56(d,J=8Hz,1H),8.46(d,J=8Hz,1H),8.02(t,J=8Hz,1H),7.39( s,1H),7.22(d,J=8.4Hz,1H),7.09(d,J=8.4Hz,1H),4.06(t,J=8Hz,2H),2.90(t,J=8.4Hz,2H). [ka]

[0179] Example 26: To a solution of 1-oxo-2H-phthalazine-5-sulfonyl chloride (0.5 g, 2.04 mmol) in DCM (15 mL) was added TEA (426 μL, 3.07 mmol) and indoline-6-carbonitrile (235 mg, 1.63 mmol). The mixture was stirred at 25 °C under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (20 mL) and extracted with EtOAc (80 mL x 2). The combined organic layer was washed with saturated brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate = 10:1 to 0:1). Compound 26, 1-[(1-oxo-2H-phthalazin-5-yl)sulfonyl]indoline-6-carbonitrile (30 mg, 81.6 μmol, 3.99% yield) was obtained as a yellow solid. LC-MS: [M+1] 352.06.

[0180] 1 H NMR(400MHz,DMSO-d6):δ 13.09(s,1H),8.81(s,1H),8.56(d,J=8Hz,2H),8.01(t,J=8Hz,1H),7.72(s,1H),7.52 (d,J=9.2Hz,1H),7.41(d,J=7.6Hz,1H),4.08(t,J=8.4Hz,2H),3.03(t,J=8.4Hz,2H). [ka]

[0181] Compound 27-To a mixture of 4-chloroisoquinoline (5 g, 30.56 mmol, 1 equiv.) in 2H2SO4 (20 mL) was added KNO3 (3.40 g, 33.62 mmol, 1.1 equiv.) under N2 at 0°C. The mixture was stirred at 15°C for 12 h. The reaction mixture was added to ice-cold water (100 mL), then saturated NaOH solution was added until the pH was adjusted to pH=10. The mixture was extracted with EtOAc (200 mL*2). The combined organic layers were washed with brine (200 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was washed with a mixed solvent of petroleum ether / ethyl acetate=1 / 1 (50 mL). The mixture was filtered and concentrated under reduced pressure to give a residue. Compound 27-2, 4-chloro-5-nitro-isoquinoline (4 g, 19.18 mmol, 62.74% yield) was obtained as a yellow solid.

[0182] Compound 27-3: To a solution of 4-chloro-5-nitro-isoquinoline (4 g, 19.18 mmol, 1 equiv) and NH4Cl (8.21 g, 153.40 mmol, 8 equiv) in THF (50 mL) and H2O (25 mL), Zn (10.03 g, 153.40 mmol, 8 equiv) was added at 0 °C. The resulting mixture was stirred at 15 °C for 3 h. The reaction mixture was filtered, and the filtrate was added to H2O (200 mL) and extracted with EtOAc (150 mL*2). The combined organic layers were washed with brine (200 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 0 / 1). Compound 27-3, 4-chloroisoquinolin-5-amine (1.5 g, 8.40 mmol, 43.79% yield) was obtained as a pale yellow solid.

[0183] Preparation of solution 1: To a mixture of 4-chloroisoquinolin-5-amine (1.5 g, 8.40 mmol, 1 equiv) in concentrated HCl (15 mL) was added NaNO2 (579.45 mg, 8.40 mmol, 1 equiv) in one portion under N2 at -5 °C. The mixture was stirred at -5 °C for 1 h.

[0184] Preparation of solution 2: SO2 was bubbled into a solution of CuCl (207.85 mg, 2.10 mmol, 0.25 equiv) in HOAc (15 mL) and H2O (3 mL) at 0 °C for 30 min.

[0185] Compound 27-4: To solution 1, solution 2 was added slowly. The mixture was stirred at 15° C. for 2 h. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with H2O (500 mL) and extracted with DCM (300 mL*3). The combined organic layers were washed with brine (500 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue that was used without further purification. Compound 27-4, 4-chloroisoquinoline-5-sulfonyl chloride (1.5 g, crude) was obtained as a yellow solid.

[0186] Compound 27-5: To a mixture of 4-chloroisoquinoline-5-sulfonyl chloride (1.5 g, 5.72 mmol, 1 equiv) and indoline-6-carbonitrile (825.06 mg, 5.72 mmol, 1 equiv) in DMF (20 mL) was added K2CO3 (1.58 g, 11.45 mmol, 2 equiv) in one portion at 15 °C under N2. The mixture was stirred at 15 °C for 12 h. The reaction mixture was diluted with H2O (200 mL) and extracted with EtOAc (150 mL, *3). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 0 / 1). Compound 27-5, 1-[(4-chloro-5-isoquinolyl)sulfonyl]indoline-6-carbonitrile (600 mg, crude) was obtained as a yellow solid.

[0187] Compound 27-6: To a solution of 1-[(4-chloro-5-isoquinolyl)sulfonyl]indoline-6-carbonitrile (600 mg, 1.62 mmol, 1 equiv.) in DCM (20 mL) was added m-CPBA (769.93 mg, 3.57 mmol, 80% purity, 2.2 equiv.). The mixture was stirred at 15 °C for 12 h. The reaction mixture was directly purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to ethyl acetate:EtOH = 3:1). The crude product of compound 27-6 was obtained, triturated with MeOH (50 mL), filtered, and used in the next step without further purification.

[0188] Example 27: A mixture of 1-(4-chloro-2-oxido-isoquinolin-2-ium-5-yl)sulfonylindoline-6-carbonitrile (150 mg, 388.78 μmol, 1 equiv.) in Ac2O (15 mL) was heated to 100° C. and stirred for 12 h. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by preparative HPLC (column: Xtimate C18 150*25 mm*5 μm; mobile phase: [water (10 mM NH4HCO3)-ACN]; B%: 40%-70%, 10 min). The residue was then re-purified by preparative HPLC (column: Xtimate C18 150*25 mm*5 μm; mobile phase: [water (10 mM NH4HCO3)-ACN]; B%: 30%-55%, 8 min). Example 27, 1-[(4-chloro-1-oxo-2H-isoquinolin-5-yl)sulfonyl]indoline-6-carbonitrile (4 mg, 9.63 μmol, 2.48% yield, 92.93% purity) was obtained as a yellow solid. LCMS (ESI+) m / z: 383.0.

[0189] 1 H NMR(400MHz,DMSO-d6):8.55(d,J=8 Hz,1H),7.98(d,J=7.6 Hz,1H),7.63-7.46(m,4H),7.21(s,1H),4.15(t,J=8.6 Hz,2H),3.34(t,J=8.8 Hz,2H). [ka]

[0190] Compound 28-2: To a solution of 6-chloro-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine (1.6 g, 10.35 mmol, 1 equiv) in DCM (20 mL), Boc2O (6.78 g, 31.05 mmol, 7.13 mL, 3 equiv), TEA (2.09 g, 20.70 mmol, 2.88 mL, 2 equiv), and DMAP (1.26 g, 10.35 mmol, 1 equiv) were added at 20 °C. The mixture was heated to 50 °C and stirred for 12 h. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 0 / 1). Compound 28-2, tert-butyl 6-chloro-2,3-dihydropyrrolo[3,2-c]pyridine-1-carboxylate (1.5 g, 5.89 mmol, 56.90% yield) was obtained as a colorless oil.

[0191] Compound 28-3: To a solution of tert-butyl 6-chloro-2,3-dihydropyrrolo[3,2-c]pyridine-1-carboxylate (1.5 g, 5.89 mmol, 1 equiv.) in MeOH (50 mL) and DIPEA (5 mL) was added Pd(dppf)Cl2.CH2Cl2 (2.40 g, 2.94 mmol, 0.5 equiv.) at 15 °C. The suspension was degassed under vacuum and purged with CO several times. The mixture was stirred under CO (50 psi) at 80 °C for 12 h. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 0 / 1). Compound 28-3, O1-tert-butyl O6-methyl 2,3-dihydropyrrolo[3,2-c]pyridine-1,6-dicarboxylate (1.5 g, 4.31 mmol, 73.22% yield, 80% purity), was obtained as a red solid.

[0192] Compound 28-4: To a solution of O1-tert-butyl O6-methyl 2,3-dihydropyrrolo[3,2-c]pyridine-1,6-dicarboxylate (1.57 g, 5.64 mmol, 1 equiv) in MeOH (20 mL) and HO (4 mL), NaOH (676.96 mg, 16.92 mmol, 3 equiv) was added. The mixture was stirred at 15 °C for 30 min. The reaction mixture was concentrated under reduced pressure to remove MeOH. To the remaining solution was then added 12 M HCl solution until pH = 3-4, and the mixture was extracted with EtOAc (100 mL*2). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue that was used without further purification. Compound 28-4, 1-tert-butoxycarbonyl-2,3-dihydropyrrolo[3,2-c]pyridine-6-carboxylic acid (700 mg, crude) was obtained as a yellow solid.

[0193] Compound 28-5: To a solution of 1-tert-butoxycarbonyl-2,3-dihydropyrrolo[3,2-c]pyridine-6-carboxylic acid (650 mg, 2.46 mmol, 1 equiv) in DMF (10 mL) was added HATU (1.40 g, 3.69 mmol, 1.5 equiv), NH4Cl (526.24 mg, 9.84 mmol, 4 equiv) and DIPEA (1.59 g, 12.30 mmol, 2.14 mL, 5 equiv). The mixture was stirred at 15 °C for 12 h. The reaction mixture was added to H2O (150 mL) and extracted with EtOAc (80 mL*2). The combined organic layers were washed with brine (150 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=1 / 0 to 0 / 1). Compound 28-5, tert-butyl 6-carbamoyl-2,3-dihydropyrrolo[3,2-c]pyridine-1-carboxylate (300 mg, 46% yield) was obtained as a white solid.

[0194] Compound 28-6: To a solution of tert-butyl 6-carbamoyl-2,3-dihydropyrrolo[3,2-c]pyridine-1-carboxylate (250 mg, 949.52 μmol, 1 equiv) in THF (10 mL) was added pyridine (195.28 mg, 2.47 mmol, 199.26 μL, 2.6 equiv) and TFAA (518.51 mg, 2.47 mmol, 343.38 μL, 2.6 equiv). The mixture was stirred at 15 °C for 2 h. The reaction mixture was added to H2O (100 mL) and extracted with EtOAc (50 mL*2). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 1:1). Compound 28-6, tert-butyl 6-cyano-2,3-dihydropyrrolo[3,2-c]pyridine-1-carboxylate (250 mg, crude) was obtained as a pale yellow solid.

[0195] Compound 28-7: A solution of tert-butyl 6-cyano-2,3-dihydropyrrolo[3,2-c]pyridine-1-carboxylate (250 mg, 1.02 mmol, 1 equiv) in HCl / EtOAc (10 mL) was stirred at 15° C. for 12 h. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was used without further purification. Compound 28-7, 2,3-dihydro-1H-pyrrolo[3,2-c]pyridine-6-carbonitrile (160 mg, crude, HCl) was obtained as an off-white solid.

[0196] Compound 28-8: A mixture of 1-hydroxyisoquinoline-5-sulfonic acid (1.00 g, 4.44 mmol, 1 equiv) in SOCl2 (10 mL) and DMF (0.1 mL) was heated to 40 °C and stirred for 1 h. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with H2O (100 mL) and extracted with DCM (70 mL*2). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give the residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 0 / 1). Compound 28-8, 1-oxo-2H-isoquinoline-5-sulfonyl chloride (300 mg, crude) was obtained as a yellow solid, which was used directly in the next step.

[0197] Example 28: To a solution of 2,3-dihydro-1H-pyrrolo[3,2-c]pyridine-6-carbonitrile (37.53 mg, 258.55 μmol, 0.7 equiv) in DMF (7 mL) was added NaH (59.10 mg, 1.48 mmol, 78.02 μL, 60% purity, 4 equiv) at 15° C. The mixture was stirred at this temperature for 30 min, and then 1-oxo-2H-isoquinoline-5-sulfonyl chloride (90 mg, 369.36 μmol, 1 equiv) was added at 15° C. The resulting mixture was stirred at 15° C. for 1.5 h. The reaction mixture was quenched by adding H2O (20 mL), then diluted with H2O (40 mL) and extracted with EtOAc (20 mL*2). The combined organic layers were washed with brine (60 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Xtimate C18 150*25mm*5μm; mobile phase: [water (10mM NH4HCO3)-ACN]; B%: 20%-50%, 8 min). Example 28, 1-[(1-oxo-2H-isoquinolin-5-yl)sulfonyl]-2,3-dihydropyrrolo[3,2-c]pyridine-6-carbonitrile (3 mg, purity 98.76%) was obtained as a white solid. LCMS(ESI+) / mz: 353.0.

[0198] 1H NMR(400MHz,DMSO-d6):δ 11.74(br,1H),8.56(d,J=8Hz,1H),8.51~8.46(m,2H),7.75(s,1H),7.67(t,J=8Hz,1H) ,7.45~7.37(m,1H),7.11(d,J=7.6Hz,1H),4.10(t,J=8.8Hz,2H),3.22(t,J=8.6Hz,2H). [ka]

[0199] Compound 29-2: To a solution of 4-methoxy-1H-indole-6-carbonitrile (230 mg, 1.34 mmol, 1 equiv) in DCM (8 mL) was added triethylsilane (776.63 mg, 6.68 mmol, 1.07 mL, 5 equiv). The reaction was then cooled to 0 °C and TFA (4 mL) was added dropwise at 0 °C. The mixture was heated to 50 °C and stirred for 12 h. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 0 / 1). Compound 29-2, 4-methoxyindoline-6-carbonitrile (100 mg, 40% yield) was obtained as a pale yellow solid.

[0200] Example 29: To a solution of 1-oxo-2H-isoquinoline-5-sulfonyl chloride (150 mg, 615.60 μmol, 1 eq) and 4-methoxyindoline-6-carbonitrile (32.17 mg, 184.68 μmol, 0.3 eq) in DCM (10 mL) was added TEA (207.64 mg, 1.23 mmol, 285.61 μL, 60% purity, 2 eq). The mixture was stirred at 15° C. for 12 h. The reaction mixture was added to H2O (50 mL) and extracted with EtOAc (30 mL*2). The combined organic layers were concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Nano-micro Kromasil C18 100*40mm 10μm; mobile phase: [water (0.1% TFA)-ACN]; B%: 30%-56%, 10min). The residue was re-purified by preparative HPLC (column: Xtimate C18 150*25mm*5μm; mobile phase: [water (10mM NH4HCO3)-ACN]; B%: 25%-55%, 8min). Example 29, 4-methoxy-1-[(1-oxo-2H-isoquinolin-5-yl)sulfonyl]indoline-6-carbonitrile (2mg, 96.64% purity) was obtained as a white solid. LCMS (ESI+) m / z: 382.0.

[0201] 1 H NMR(400MHz,DMSO-d6):δ 11.68(br,1H),8.52(d,J=8Hz,1H),8.34(d,J=7.6Hz,1H),7.64(t,J=8Hz,1H),7.38(d,J=7.6Hz,1H),7. 26(s,1H),7.21(s,1H),7.13(d,J=7.6Hz,1H),4.07(t,J=8.6Hz,2H),3.82(s,3H),2.99(t,J=8.6Hz,2H). [ka]

[0202] Compound 30-2: To a solution of 4-nitro-1H-indole-6-carbonitrile (1.00 g, 5.34 mmol, 1 equiv) in EtOH (20 mL), Pd / C (1.00 g, 106.86 μmol, 5% wt%) was added under N2. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (15 psi) at 15 °C for 1.5 h. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give a residue that was used without further purification. Compound 30-2, 4-amino-1H-indole-6-carbonitrile (700 mg, 4.45 mmol, 83.35% yield) was obtained as a yellow solid.

[0203] Compound 30-3: To a solution of 4-amino-1H-indole-6-carbonitrile (700 mg, 4.45 mmol, 1 equiv) in DCM (15 mL), TEA (1.35 g, 13.36 mmol, 1.86 mL, 3 equiv) and acetyl chloride (419.54 mg, 5.34 mmol, 381.40 μL, 1.2 equiv) were added. The mixture was stirred at 15 °C for 2 h. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified twice by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 0 / 1). Compound 30-3, N-(6-cyano-1H-indol-4-yl)acetamide (600 mg, 3.01 mmol, 67.63% yield) was obtained as a pale yellow solid.

[0204] Compound 30-4: To a solution of N-(6-cyano-1H-indol-4-yl)acetamide (600 mg, 3.01 mmol, 1 equiv) in DCM (20 mL) was added TESH (3.50 g, 30.12 mmol, 4.81 mL, 10 equiv). The reaction was then cooled to 0 °C and TFA (10 mL) was added dropwise at 0 °C. The resulting mixture was stirred at 15 °C for 12 h. The mixture was heated to 50 °C and stirred for 5 h. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 0 / 1). Compound 30-4, N-(6-cyanoindolin-4-yl)acetamide (400 mg, 1.99 mmol, 66.00% yield) was obtained as a pale yellow solid.

[0205] Example 30: To a solution of 1-oxo-2H-isoquinoline-5-sulfonyl chloride (200 mg, 820.79 μmol, 1 eq) in DCM (10 mL) was added TEA (332.22 mg, 3.28 mmol, 456.98 μL, 4 eq) and N-(6-cyanoindolin-4-yl)acetamide (82.58 mg, 410.40 μmol, 0.5 eq). The mixture was stirred at 15° C. for 12 h. The reaction mixture was added to H2O (150 mL) and extracted with EtOAc (80 mL*2). The combined organic layers were concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=1 / 0, DCM:MeOH=2:1). The residue was re-purified by preparative HPLC (column: Xtimate C18 150*25mm*5μm; mobile phase: [water (10mM NH4HCO3)-ACN]; B%: 20%-50%, 8min). Example 30, N-[6-cyano-1-[(1-oxo-2H-isoquinolin-5-yl)sulfonyl]indolin-4-yl]acetamide (20mg, 96.9% purity) was obtained as a white solid. LCMS (ESI+) m / z: 409.1.

[0206] 1 H NMR(400MHz,DMSO-d6):δ 11.67(br,1H),9.58(s,1H),8.49(d,J=8Hz,1H),8.33(d,J=8Hz,1H),7.83(s,1H),7.61(t,J=8Hz,1H) ,7.36~7.28(m,2H),7.07(d,J=7.2Hz,1H),4.04(t,J=8.4Hz,2H),2.97(t,J=8.4Hz,2H),2.03(s,1H).

[0207] Example 31: A mixture of N-[6-cyano-1-[(1-oxo-2H-isoquinolin-5-yl)sulfonyl]indolin-4-yl]acetamide (40 mg, 97.94 μmol, 1 equiv.) in concentrated HCl (6 mL) and EtOH (6 mL) was heated to 50° C. and stirred for 4.5 h. The reaction mixture was added to aqueous Na2CO3 until pH>7, then diluted with H2O (20 mL) and extracted with DCM (50 mL*2). The combined organic layers were concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Welch Ultimate AQ-C18 150*30 mm*5 μm; mobile phase: [water (0.1% TFA)-ACN]; B%: 25%-55%, 12 min). Example 31, 4-amino-1-[(1-oxo-2H-isoquinolin-5-yl)sulfonyl]indoline-6-carbonitrile (14 mg, 98.04% purity, TFA salt) was obtained as a white solid. LCMS (ESI+) m / z: 367.1.

[0208] 1 H NMR(400MHz,DMSO-d6):δ 11.69(d,J=5.6Hz,1H),8.51(d,J=7.6Hz,1H),8.27(d,J=7.6Hz,1H),7.63(t,J=7.8Hz,1H),7.37(t,J=6.8Hz,1 H),7.13(d,J=7.6Hz,1H),6.78(s,1H),6.61(s,1H),5.65(br,2H),4.05(t,J=8.4Hz,2H),2.77(t,J=8.4Hz,2H). [ka]

[0209] Compound 32-2: Three reaction mixtures were prepared in parallel as follows: To a solution of 4-bromoisoquinoline (100 g, 480.64 mmol, 1 equiv) in H2SO4 (250 mL) was added KNO3 (53.45 g, 528.71 mmol, 1.1 equiv) at 0°C. The mixture was stirred at 25°C for 12 h under N2 atmosphere. The reaction mixture was quenched by adding ice water (1 L) at 0°C, then aqueous NaOH (800 mL) was added to the mixture to adjust the pH to about 8. The mixture was filtered and the filter cake was concentrated under reduced pressure to give a residue. The residue was triturated with petroleum ether: EtOAc = 1: 1.5 (2.5 L) at 25°C for 12 h. After filtration, the solid was triturated with H2O (1.5 L) at 25°C for 5 h. Compound 32-2, 4-bromo-5-nitro-isoquinoline (200 g, 790.35 mmol, 54.81% yield) was obtained as a yellow solid. LCMS (ESI+) m / z: 252.9.

[0210] Compound 32-3: Two reaction mixtures were prepared in parallel as follows: A mixture of 4-bromo-5-nitro-isoquinoline (50 g, 197.59 mmol, 1 equiv), Cs2CO3 (128.76 g, 395.18 mmol, 2 equiv), Pd(dppf)Cl2 (14.46 g, 19.76 mmol, 0.1 equiv), and MeB(OH)2 (23.66 g, 395.18 mmol, 2 equiv) in dioxane (400 mL) and H2O (40 mL) was degassed and purged with N2 three times, then the mixture was stirred at 110 °C under N2 atmosphere for 12 h. Two batches of the same scale (50 g) were run in parallel and workup / purification was carried out together. The reaction mixture was concentrated under reduced pressure to remove dioxane. The residue was diluted with H2O (1.5 L) and extracted with EtOAc (2 L*3). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=10 / 1 to 1:1). Compound 32-3, 4-methyl-5-nitro-isoquinoline (40 g, 212.56 mmol, 53.79% yield) was obtained as a yellow solid.

[0211] Compound 32-4: To a solution of 4-methyl-5-nitro-isoquinoline (60 g, 318.84 mmol, 1 eq) in DCM (800 mL) was added m-CPBA (151.31 g, 701.44 mmol, 80% purity, 2.2 eq) at 0° C. The mixture was stirred at 25° C. for 12 h. The reaction mixture was quenched by adding aqueous Na2SO3 (900 mL). The reaction mixture was diluted with H2O (1 L) and extracted with DCM (2000 mL*4). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with EtOAc (2000 mL) at 25° C. for 2 h, and the solid was dried under reduced pressure. Compound 32-4, 4-methyl-nitro-2-oxide-isquinolin-2-ium (40 g, 195.90 mmol, 61.44% yield) was obtained as a yellow solid.

[0212] Compound 32-5: To a solution of 4-methyl-5-nitro-2-oxide-isoquinolin-2-ium (45 g, 220.39 mmol, 1 equiv) in DCM (500 mL) was added POCl3 (40.55 g, 264.47 mmol, 24.58 mL, 1.2 equiv) and DMF (8.05 g, 110.20 mmol, 8.48 mL, 0.5 equiv) at 0 °C. The mixture was stirred at 20 °C under N2 atmosphere for 12 h. The reaction mixture was concentrated under reduced pressure to remove DCM. The residue was quenched with H2O (300 mL) and then filtered. The filter cake was dried under reduced pressure to give a residue which was used without further purification. The crude product, compound 32-5, 1-chloro-4-methyl-5-nitro-isoquinoline (27 g, crude) was obtained as a yellow solid. LCMS(ESI+)m / z:222.9.

[0213] Compound 32-6: A mixture of 1-chloro-4-methyl-5-nitro-isoquinoline (27 g, 121.28 mmol, 1 equiv.), NaOMe (13.10 g, 242.56 mmol, 2 equiv.) in MeOH (500 mL) was degassed and purged with N2 three times, then the mixture was stirred at 80 °C under N2 atmosphere for 5 h. The reaction mixture was concentrated under reduced pressure to remove MeOH. The residue was diluted with H2O (500 mL) and extracted with EtOAc (600 mL*4). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give the residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=1 / 0 to 5:1). Compound 32-6, 1-methoxy-4-methyl-5-nitro-isoquinoline (15 g, 68.74 mmol, 56.68% yield), was obtained as a yellow solid.

[0214] Compound 32-7: To a solution of 1-methoxy-4-methyl-5-nitro-isoquinoline (15 g, 68.74 mmol, 1 equiv.) in MeOH (210 mL) and HO (70 mL), Zn (22.48 g, 343.71 mmol, 5 equiv.) and NH4Cl (18.39 g, 343.71 mmol, 5 equiv.) were added at 0 °C. The mixture was stirred at 25 °C for 12 h. The mixture was filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10 / 1 to 1:1). Compound 32-7, 1-methoxy-4-methyl-isoquinolin-5-amine (10 g, 53.13 mmol, 77.29% yield) was obtained as a brown solid. LCMS (ESI+) m / z: 189.0.

[0215] Compound 32-8: To a solution of 1-methoxy-4-methyl-isoquinolin-5-amine (2 g, 10.63 mmol, 1 equiv) in HCl (80 mL) was added NaNO2 (903.12 mg, 10.63 mmol, 1 equiv) in H2O (5 mL) at -5 °C. The mixture was stirred at -5 °C for 1 h and transferred in one portion to a solution of CuCl (262.98 mg, 2.66 mmol, 63.52 μL, 0.25 equiv) in H2O (5 mL) saturated with SO2 in AcOH (50 mL). The mixture was stirred at 20 °C for 2 h. The reaction mixture was quenched by adding to ice water (100 mL) at 0 °C, and then the mixture was extracted with DCM (200 mL * 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue that was used without further purification. Compound 32-8, 1-methoxy-4-methyl-isoquinoline-5-sulfonyl chloride (1.5 g, crude) was obtained as a yellow solid. LCMS (ESI+) m / z: 271.9.

[0216] Compound 32-9: To a mixture of N-(6-cyanoindolin-4-yl)acetamide (888.67 mg, 4.42 mmol, 1.2 equiv) and pyridine (1.05 g, 13.25 mmol, 1.07 mL, 3.6 equiv) was added a solution of 1-methoxy-4-methylisoquinoline-5-sulfonyl chloride (780 mg, 2.87 mmol, 0.78 equiv) in DCM (10 mL) dropwise at -5°C. The mixture was degassed and purged with N2 three times, then the mixture was stirred under N2 atmosphere at 15°C for 12 h. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. Crude compound 32-9, N-(6-cyano-1-((1-methoxy-4-methylisoquinolin-5-yl)sulfonyl)indolin-4-yl)acetamide (1.2 g, crude), was obtained as a brown solid and used in the next step without further purification.

[0217] Example 32: A mixture of N-(6-cyano-1-((1-methoxy-4-methylisoquinolin-5-yl)sulfonyl)indolin-4-yl)acetamide (600 mg, 1.37 mmol, 1 equiv) and TMSI (1.10 g, 5.50 mmol, 748.43 μL, 4 equiv) in ACN (10 mL) was stirred at 15° C. for 1 h under N2 atmosphere. The reaction mixture was quenched by adding H2O (30 mL) at 0° C., then extracted with EtOAc (30 mL*2). The combined organic layers were washed with brine (60 mL*1), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative TLC (SiO2, DCM:MeOH=10:1) and then re-purified by preparative HPLC (column: Waters Xbridge BEH C18 100*25mm*5μm; mobile phase: [water (10mM NH4HCO3)-ACN]; B%: 15%-50%, 8min). Example 32, N-(6-cyano-1-((4-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)sulfonyl)indolin-4-yl)acetamide (4mg, 9.46μmol, 99.9% purity) was obtained as a white solid. LCMS(ESI+)m / z:423.1.

[0218] 1 H NMR(400MHz,DMSO-d6):δ 11.69(br,1H),9.74(s,1H),8.59(d,J=4Hz,1H),7.98~7.85(m,2H),7.52(t,J=7.6Hz,1H),7.2 4(s,1H),6.99(s,1H),4.22(t,J=8.4Hz,2H),~3.31(2H,mixed with solvent peak),2.59(s,3H),2.14(s,3H).

[0219] Example 33: A solution of N-(6-cyano-1-((4-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)sulfonyl)indolin-4-yl)acetamide (30 mg, 71.01 μmol, 1 equiv.) in concentrated HCl (5 mL) and EtOH (5 mL) was stirred at 50° C. for 5 h. To the reaction mixture was added saturated Na2CO3 solution at 0° C. until pH=8, then extracted with EtOAc (60 mL*5). The combined organic layers were washed with brine (200 mL*1), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Waters Xbridge BEH C18 100*25 mm*5 μm; mobile phase: [water (10 mM NH4HCO3)-ACN]; B%: 20%-50%, 8 min). Example 33, 4-amino-1-((4-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)sulfonyl)indoline-6-carbonitrile (3.8 mg, 9.87 μmol, 13.89% yield, 98.77% purity) was obtained as a white solid. LCMS (ESI+) m / z: 381.0.

[0220] 1 H NMR(400MHz,DMSO-d6):δ 11.66(br,1H),8.57(d,J=7.6Hz,1H),7.81(d,J=7.6Hz,1H),7.53(t,J=7.8Hz,1H),7.23(s,1H), 6.64(s,1H),6.48(s,1H),5.79(s,2H),4.17(t,J=8.4Hz,2H),3.07(t,J=8.4Hz,2H),2.59(s,3H).

[0221] Example 34: To a solution of 4-amino-1-((4-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)sulfonyl)indoline-6-carbonitrile (20 mg, 52.57 μmol, 1 eq.) in DMF (2 mL), pyridine (12.48 mg, 157.72 μmol, 12.73 μL, 3 eq.) and MeI (74.62 mg, 525.74 μmol, 32.73 μL, 10 eq.) were added. The mixture was then stirred at 25° C. for 12 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Waters Xbridge BEH C18 100*25 mm*5 μm; mobile phase: [water (10 mM NH4HCO3)-ACN]; B%: 30%-60%, 8 min). 4-(Dimethylamino)-1-((4-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)sulfonyl)indoline-6-carbonitrile (2.1 mg, 5.09 μmol, 9.68% yield, 99% purity) was obtained as a white solid. LCMS (ESI+) m / z: 409.0.

[0222] 1 H NMR(400MHz,DMSO-d6):δ 11.68(br,1H),8.59(d,J=7.6Hz 1H),7.86(d,J=7.6Hz,1H),7.53(t,J=8Hz,1H),7.24(s,1H),6.93(s,1H),6.78 (s, 1H), 4.17 (t, J=8.4Hz, 2H), ~3.05 (2H, mixed with solvent peak), 2.87 (s, 6H), 2.61 (s, 3H). [ka]

[0223] Compound 35-2: To a solution of 4-chloroisoquinoline (40 g, 244.49 mmol, 1 eq) in H2SO4 (110 mL), a solution of KNO3 (32.13 g, 317.84 mmol, 1.3 eq) in H2SO4 (140 mL) was slowly added dropwise at -5°C. The mixture was stirred at 0°C for 1 h, then at 15°C for 12 h. The mixture was poured into ice water (3 L), and then solid Na2CO3 was added to the mixture until pH=8. A yellow solid was precipitated, filtered, the filter cake was washed with H2O (2000 mL*3), and the filter cake was concentrated. The filter cake was dissolved in EtOAc, the EtOAc was filtered, and the filter cake was concentrated under reduced pressure to give a residue. Crude compound 35-2, 4-chloro-5-nitroisoquinoline (43 g, 206.14 mmol, 84.31% yield) was obtained as a yellow solid.

[0224] Compound 35-3: To a solution of 4-chloro-5-nitroisoquinoline (43 g, 206.14 mmol, 1 eq.) in CHCl3 (500 mL), m-CPBA (88.93 g, 412.27 mmol, 80% purity, 2 eq.) was added in several portions at 0°C. The mixture was stirred at 15°C for 12 h. To the mixture, saturated NaHCO3 (1 L) was added at 0°C, the mixture was extracted with CHCl3 / MeOH=10 / 1 (500 mL*4), then the organic layer was washed with 15% aqueous Na2S2SO4 (500 mL*4), the combined organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=1 / 1 to 0 / 1). Compound 35-3, 4-chloro-5-nitroisoquinoline 2-oxide (36 g, 160.28 mmol, 77.76% yield) was obtained as a yellow solid.

[0225] Compound 35-4: To a solution of 4-chloro-5-nitroisoquinoline 2-oxide (36 g, 160.28 mmol, 1 eq) in DCM (500 mL) was added POCl3 (49.15 g, 320.57 mmol, 29.79 mL, 2 eq) slowly at 0 °C. The mixture was stirred at 60 °C under N2 atmosphere for 12 h. The mixture was added to water (1000 mL) and extracted with DCM (500 mL * 3). The organic layer was washed with saturated NaHCO3 (800 mL * 3) and brine (1500 mL), then dried over Na2SO4, filtered and concentrated. Crude compound 35-4, 1,4-dichloro-5-nitroisoquinoline (26 g, 106.98 mmol, 66.74% yield) was obtained as a brown solid.

[0226] Compound 35-5: To a solution of 1,4-dichloro-5-nitroisoquinoline (25 g, 102.86 mmol, 1 equiv.) in MeOH (150 mL), NaOMe (24.45 g, 113.15 mmol, 25% purity, 1.1 equiv.) was added. The mixture was stirred at 80° C. under N2 atmosphere for 1 h, filtered, and the filter cake was concentrated under reduced pressure to give compound 36-5, 4-chloro-1-methoxy-5-nitroisoquinoline (16 g, 67.05 mmol, 65.19% yield) as a brown solid.

[0227] Compound 35-6: To a solution of 4-chloro-1-methoxy-5-nitroisoquinoline (15.9 g, 66.63 mmol, 1 eq) and NH4Cl (35.64 g, 666.31 mmol, 10 eq) in MeOH (200 mL) and HO (40 mL), Zn (43.57 g, 666.31 mmol, 10 eq) was added slowly at 0 °C. The mixture was stirred at 15 °C for 2 h, filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was added to HO (50 mL) and the mixture was extracted with EtOAc (500 mL * 4). The combined organic layers were washed with brine (2000 mL * 1), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was washed with petroleum ether / ethyl acetate = 30:1 (930 mL), filtered, and the filter cake was dried under reduced pressure. Crude compound 36-6, 4-chloro-1-methoxyisoquinolin-5-amine (11.2 g, 53.68 mmol, 80.56% yield) was obtained as a white solid.

[0228] Preparation of solution A: To a solution of 4-chloro-1-methoxyisoquinolin-5-amine (0.2 g, 958.57 μmol, 1 equiv) in HCl (8 mL) was added a solution of NaNO (99.21 mg, 1.44 mmol, 1.5 equiv) in HO (1 mL) at −5° C. The mixture was stirred at −5° C. for 1 h.

[0229] Preparation of solution B: SO2 was bubbled into a solution of CuCl (23.72 mg, 239.64 μmol, 5.73 μL, 0.25 equiv) in AcOH (5 mL) and HO (1 mL) at 0 °C for 30 min at 15 psi.

[0230] Compound 35-7: Solution A was transferred to solution B, and the mixture was stirred at 15° C. for 2 h. The reaction mixture was quenched by adding to ice water (20 mL) at 0° C., then extracted with DCM (30 mL*3). The combined organic layers were washed with brine (100 mL*2), dried over Na2SO, filtered, and concentrated under reduced pressure to give a residue. Compound 35-7, 4-chloro-1-methoxyisoquinoline-5-sulfonyl chloride (300 mg, crude) was obtained as a yellow solid.

[0231] Compound 35-9: To a mixture of N-(6-cyanoindolin-4-yl)acetamide (compound 35-8; 500 mg, 2.48 mmol, 1.3 equiv) and pyridine (453.57 mg, 5.73 mmol, 462.83 μL, 3 equiv) was added a solution of 4-chloro-1-methoxyisoquinoline-5-sulfonyl chloride (1.27 g, 1.91 mmol, 1 equiv) in DCM (5 mL) dropwise at −5° C. The mixture was degassed and purged with N2 three times, and the mixture was stirred under N2 atmosphere at 15° C. for 12 h. The reaction mixture was concentrated under reduced pressure to give a residue. Crude compound 35-9, N-(1-((4-chloro-1-methoxyisoquinolin-5-yl)sulfonyl)-6-cyanoindolin-4-yl)acetamide (1.5 g, crude), was obtained as a red solid and used in the next step without further purification.

[0232] Example 35: A mixture of N-(1-((4-chloro-1-methoxyisoquinolin-5-yl)sulfonyl)-6-cyanoindolin-4-yl)acetamide (100 mg, 218.87 μmol, 1 eq) and TMSI (218.96 mg, 1.09 mmol, 148.96 μL, 5 eq) in ACN (10 mL) was stirred at 80° C. for 2 h under N2 atmosphere. The reaction mixture was quenched by adding H2O (20 mL) at 0° C., then extracted with EtOAc (40 mL*2). The combined organic layer was washed with brine (80 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by preparative TLC (SiO2, DCM:MeOH=10:1). The residue was then re-purified by preparative HPLC (column: Waters Xbridge BEH C18 100*25mm*5μm; mobile phase: [water (10mM NH4HCO3)-ACN]; B%: 20%-50%, 8min). Example 35, N-(1-((4-chloro-1-oxo-1,2-dihydroisoquinolin-5-yl)sulfonyl)-6-cyanoindolin-4-yl)acetamide (1.9mg, 4.08μmol, 1.86% yield, 95.1% purity) was obtained as a white solid. LCMS (ESI+) m / z: 443.0.

[0233] NMR(400MHz,DMSO-d6):δ 9.73(s,1H),8.57(d,J=7.6Hz,1H),8.01(d,J=8Hz,1H),7.91(s,1H),7.66(s,1H),7.63( t,J=7.6Hz,1H),6.98(s,1H),4.19(t,J=8.4Hz,2H),~3.20(2H,mixed with solvent peak),2.14(s,3H).

[0234] Example 36: A solution of N-(1-((4-chloro-1-oxo-1,2-dihydroisoquinolin-5-yl)sulfonyl)-6-cyanoindolin-4-yl)acetamide (16 mg, 36.13 μmol, 1 equiv.) in concentrated HCl (3 mL) and EtOH (3 mL) was stirred at 50° C. for 5 h. To the mixture was added saturated Na2CO3 solution at 0° C. until pH=8, and the mixture was extracted with EtOAc (40 mL*5). The combined organic layers were washed with brine (200 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Waters Xbridge BEH C18 100*25 mm*5 μm; mobile phase: [water (10 mM NH4HCO3)-ACN]; B%: 20%-40%, 8 min). Example 36, 4-amino-1-((4-chloro-1-oxo-1,2-dihydroisoquinolin-5-yl)sulfonyl)indoline-6-carbonitrile (1.6 mg, 97.6% purity) was obtained as a white solid. LCMS (ESI+) m / z: 400.9.

[0235] 1 H NMR(400MHz,DMSO-d6):δ 12.04(br,1H),8.56(d,J=8Hz,1H),7.92(d,J=7.6Hz,1H),7.65~7.61(m,2H),6.6 3(s,1H),6.45(s,1H),5.77(s,2H),4.15(t,J=8.4Hz,2H),3.05(t,J=8.4Hz,2H).

[0236] Example 37: To a solution of 4-amino-1-((4-chloro-1-oxo-1,2-dihydroisoquinolin-5-yl)sulfonyl)indoline-6-carbonitrile (20 mg, 49.90 μmol, 1 eq.) in DMF (2.5 mL), pyridine (39.47 mg, 498.95 μmol, 40.27 μL, 10 eq.) and MeI (141.64 mg, 997.91 μmol, 62.12 μL, 20 eq.) were added. The mixture was stirred at 25° C. for 12 h. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Waters Xbridge BEH C18 100*25 mm*5 μm; mobile phase: [water (10 mM NH4HCO3)-ACN]; B%: 30%-60%, 8 min). Example 37, 1-((4-chloro-1-oxo-1,2-dihydroisoquinolin-5-yl)sulfonyl)-4-(dimethylamino)indoline-6-carbonitrile (3.1 mg, 7.08 μmol, 14.20% yield, 98% purity) was obtained as a white solid. LCMS (ESI+) m / z: 429.1.

[0237] 1Η NMR(400MHz,DMSO-d6):δ 12.05(br,1H),8.55(d,J=8Hz,1H),7.94(d,J=8Hz,1H),7.65(s,1H),7.63(t,J=8Hz,1H),6.9 2(s,1H),6.74(s,1H),4.13(t,J=8.4Hz,2H),~3.33(2H,mixed with solvent peak),2.85(s,6H). [ka]

[0238] Example 38: To a mixture of 2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-6-carbonitrile (21.45 mg, 147.74 μmol, 1.2 eq) and pyridine (29.22 mg, 369.36 μmol, 29.81 μL, 3 eq) was added a solution of 1-oxo-2H-isoquinoline-5-sulfonyl chloride (30 mg, 123.12 μmol, 1 eq) in DCM (3 mL) dropwise at −5° C. The mixture was degassed and purged with N2 three times, and the mixture was stirred at 25° C. under N2 atmosphere for 12 h. The reaction mixture was concentrated under reduced pressure to give a residue. The crude product was dissolved in MeOH (2 mL) at 25° C. for 10 min, filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Welch Ultimate AQ-C18 150*30mm*5pM; mobile phase: [water (0.1% TFA)-ACN]; B%: 35%-65%, 12 min). Example 38, 1-[(1-oxo-2H-isoquinolin-5-yl)sulfonyl]-2,3-dihydropyrrolo[3,2-b]pyridine-6-carbonitrile (15 mg, 41.51 μmol, 33.71% yield, 97.5% purity) was obtained as a white solid. LCMS (ESI+) m / z: 353.0.

[0239] 1 H NMR(400MHz,DMSO-d6):δ 11.71(br,1H),8.59~8.52(m,2H),8.46(d,J=7.6Hz,1H),7.90(d,J=2Hz,1H),7.64(t,J=7.6Hz, 1H),7.39(t,J=7.6Hz,1H),7.11(d,J=7.6Hz,1H),4.08(t,J=8.4Hz,2H),3.22(t,J=8.8Hz,2H). [ka]

[0240] Compound 39-2: To a mixture of 2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-6-carbonitrile (19.23 mg, 132.49 μmol, 1.2 eq) and pyridine (26.20 mg, 331.22 μmol, 26.73 μL, 3 eq) was added dropwise a solution of 1-methoxy-4-methyl-isoquinoline-5-sulfonyl chloride (30 mg, 110.41 μmol, 1 eq) in DCM (2 mL) at −5° C. The mixture was degassed and purged with N2 three times, and the mixture was stirred under N2 atmosphere at 25° C. for 12 h. The reaction mixture was concentrated under reduced pressure to remove DCM (2 mL). The residue was purified by preparative TLC (SiO2, petroleum ether / ethyl acetate=1 / 1). Compound 39-2, 1-[(1-methoxy-4-methyl-5-isoquinolyl)sulfonyl]-2,3-dihydropyrrolo[3,2-b]pyridine-6-carbonitrile (15 mg, 39.43 μmol, 35.71% yield), was obtained as a white solid.

[0241] Example 39: A mixture of 1-[(1-methoxy-4-methyl-5-isoquinolyl)sulfonyl]-2,3-dihydropyrrolo[3,2-b]pyridine-6-carbonitrile (15 mg, 39.43 μmol, 1 eq.) and TMSI (31.56 mg, 157.72 μmol, 21.47 μL, 4 eq.) in ACN (2 mL) was stirred at 25° C. for 1 h under N2 atmosphere. The reaction mixture was quenched by adding H2O (5 mL) at 0° C., then extracted with EtOAc (5 mL*2). The combined organic layer was washed with brine (5 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Waters Xbridge Prep OBD C18 150*40mm*10μm; mobile phase: [water (0.04% NH3H20+10mM NH4HCO3)-ACN]; B%: 25%~55%, 8min). Example 39, 1-[(4-methyl-1-oxo-2H-isoquinolin-5-yl)sulfonyl]-2,3-dihydropyrrolo[3,2-b]pyridine-6-carbonitrile (3.4mg, 9.28μmol, 23.53% yield, 100% purity) was obtained as a white solid. LCMS(ESI+)m / z:367.0.

[0242] 1 H NMR(400MHz,DMSO-d6):δ 11.72(br,1H),8.62~8.57(m,2H),8.02(d,J=2.4Hz,1H),7.59~7.51(m,2H) ),7.25(s,1H),4.23(t,J=8.8Hz,2H),3.49(t,J=8.8Hz,2H),2.59(s,3H). [ka]

[0243] Compound 40-2: To a mixture of 2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-6-carbonitrile (17.89 mg, 123.23 μmol, 1.2 eq.) and pyridine (24.37 mg, 308.07 μmol, 24.87 μL, 3 eq.), a solution of 4-chloro-1-methoxy-isoquinoline-5-sulfonyl chloride (30 mg, 102.69 μmol, 1 eq.) in DCM (2 mL) was added dropwise at −5° C. The mixture was degassed and purged with N2 three times, and the mixture was stirred under N2 atmosphere at 25° C. for 12 h. LC-MS showed that about 50% of the desired compound was detected. The reaction mixture was concentrated under reduced pressure to remove DCM (2 mL). The residue was purified by preparative TLC (SiO2, PE:EA=1:1). Compound 40-2, 1-[(4-chloro-1-methoxy-5-isoquinolyl)sulfonyl]-2,3-dihydropyrrolo[3,2-b]pyridine-6-carbonitrile (30 mg, 74.84 μmol, 72.88% yield) was obtained as a white solid.

[0244] Example 40: A mixture of 1-[(4-chloro-1-methoxy-5-isoquinolyl)sulfonyl]-2,3-dihydropyrrolo[3,2-b]pyridine-6-carbonitrile (30 mg, 74.84 μmol, 1 eq.) and TMSI (59.90 mg, 299.37 μmol, 40.75 μL, 4 eq.) in ACN (2 mL) was stirred at 25° C. for 1 h under N2 atmosphere. The reaction mixture was quenched by adding H2O (4 mL) at 0° C., then extracted with EtOAc (4 mL*2). The combined organic layer was washed with brine (8 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Welch Ultimate AQ-C18 150*30mm*5μm; mobile phase: [water (0.1% TFA)-ACN]; B%: 15%-45%, 12min). Example 40, 1-[(4-chloro-1-oxo-2H-isoquinolin-5-yl)sulfonyl]-2,3-dihydropyrrolo[3,2-b]pyridine-6-carbonitrile (7mg, 17.55μmol, 23.45% yield, 97% purity) was obtained as a yellow solid. LCMS(ESI+)m / z:386.9. Indoline Reagents [ka]

[0245] Indoline 2: To a mixture of 6-chloro-1H-indole (5 g, 32.98 mmol) in AcOH (80 mL), NaBH3CN (6.84 g, 108 mmol) was added at 0°C, then the mixture was stirred at 25°C under N2 atmosphere for 12 h. The reaction mixture was quenched by adding ice water (20 mL) at 0°C, then saturated aqueous NaOH was added to the mixture to adjust the pH to about 8. The mixture was extracted with EtOAc (250 mL*2). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=20:1 to 5:1). The title compound 6-chloroindoline (3 g, 19.5 mmol, 59.2% yield) was obtained as a green oil. [ka]

[0246] Indoline 4: To a mixture of 1H-indole-6-carbonitrile (5 g, 35.1 mmol) in AcOH (80 mL), NaBH3CN (7.29 g, 116.0 mmol) was added at 0°C, then the mixture was stirred at 25°C under N2 atmosphere for 12 h. The reaction mixture was quenched by adding ice water (20 mL) at 0°C. Saturated aqueous NaOH was added to the mixture to adjust the pH to about 8. The mixture was extracted with EtOAc (300 mL*2). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=10:1 to 5:1). The residue was purified by preparative HPLC (column: Xtimate C18 10μ×250mm×50mm; mobile phase: [A, water (10mM NH4HCO3)-B, ACN]; B%: 20%-40%, 25min) to give the title compound indoline-6-carbonitrile (1.9g, 13.1mmol, 37.4% yield) as a white solid. [ka]

[0247] Indoline 6: To a solution of 1H-indole-4-carbonitrile (5 g, 35.1 mmol) in THF (20 mL) was added MeLi (1.8 M, 41.9 mL). The mixture was stirred at 80 °C for 8 h under N2 atmosphere. The reaction mixture was quenched by adding H2O (100 mL) at 0 °C. The reaction mixture was extracted with DCM (400 mL x 2). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 20:1 to 1:1). The title compound 1-(1H-indol-4-yl)ethanone (2.5 g, 15.7 mmol, 44.6% yield) was obtained as a yellow solid.

[0248] Indoline 7: To a solution of 1-(1H-indol-4-yl)ethanone (2.4 g, 15.0 mmol) in THF (20 mL) was added NaBH4 (2.28 g, 60.3 mmol) at 0 °C. The mixture was stirred at 25 °C for 12 h under N2 atmosphere. The reaction mixture was quenched by adding H2O (100 mL) at 0 °C. The reaction mixture was extracted with DCM (250 mL x 2). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1:1). 1-(1H-indol-4-yl)ethanol (1 g, 6.20 mmol, 41.1% yield) was obtained as a white solid.

[0249] Indoline 8: To a mixture of 1-(1H-indol-4-yl)ethanol (1 g, 6.20 mmol) in AcOH (10 mL) was added NaBH3CN (1.29 g, 20.4 mmol) at 0 °C, then the mixture was stirred at 25 °C under N2 atmosphere for 5 h. The reaction mixture was quenched by adding ice water (15 mL) at 0 °C, then saturated aqueous NaOH was added to the mixture to adjust the pH to about 8. The reaction mixture was extracted with DCM (100 mL x 2). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10:1 to 1:1). 1-indolin-4-ylethanol (250 mg, 1.53 mmol, 24.6% yield) was obtained as a white solid. [ka]

[0250] Indoline 10: To a mixture of 4,6-dichloro-1H-indole (0.5 g, 2.69 mmol) in AcOH (5 mL) was added NaBH3CN (557 mg, 8.87 mmol) at 0 °C, then the mixture was stirred at 25 °C under N2 atmosphere for 12 h. The reaction mixture was quenched by adding ice water (20 mL) at 0 °C, then saturated aqueous NaOH was added to the mixture to adjust the pH to about 8. The reaction mixture was extracted with DCM (100 mL x 2). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 30:1 to 5:1). 4,6-dichloroindoline (0.1 g, 531.7 μmol, 19.7% yield) was obtained as a yellow oil. [ka]

[0251] Indoline 12: A mixture of 4-bromo-1H-indole-6-carbonitrile (0.1 g, 452.3 μmol), cyclopropylboronic acid (77.7 mg, 904.7 μmol), Cs2CO3 (294.7 mg, 904.7 μmol), Pd(dppf)Cl2 (33.1 mg, 45.2 μmol) in dioxane (5 mL) and H2O (0.5 mL) was degassed and purged with N2 three times. The mixture was then stirred at 110 °C under N2 atmosphere for 12 h. The reaction mixture was diluted with H2O (20 mL) and extracted with EtOAc (80 mL × 2). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 20:1 to 5:1). 4-Cyclopropyl-1H-indole-6-carbonitrile (50 mg, 274.3 μmol, 60.6% yield) was obtained as a yellow solid.

[0252] Indoline 13: To a solution of 4-cyclopropyl-1H-indole-6-carbonitrile (50 mg, 274.3 μmol) in AcOH (3 mL) was added sodium;cyanoborane (56.90 mg, 905.4 μmol) at 0° C. The mixture was stirred at 25° C. for 12 h. The reaction mixture was quenched by adding ice water (5 mL) at 0° C., and then saturated aqueous NaOH was added to the mixture to adjust the pH to about 8. The reaction mixture was extracted with DCM (50 mL×2). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by preparative TLC (SiO2, petroleum ether / ethyl acetate=5:1). The compound 4-cyclopropylindoline-6-carbonitrile (20 mg, 108.6 μmol, 39.5% yield) was obtained as a yellow solid. [ka]

[0253] Indoline 15: To a mixture of 4-bromo-1H-indole-6-carbonitrile (1 g, 4.52 mmol) in dioxane (15 mL) and H2O (1.5 mL), methylboronic acid (541.5 mg, 9.05 mmol), Cs2CO3 (2.95 g, 9.05 mmol), and Pd(dppf)Cl2 (331.0 mg, 452.3 μmol) were added in one portion. The mixture was heated to 110 °C and stirred for 12 h. The reaction mixture was diluted with H2O (300 mL) and extracted with EtOAc (150 mL × 2). The combined organic layers were washed with brine (300 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1:0 to 0:1). 4-Methyl-1H-indole-6-carbonitrile (600 mg, 3.34 mmol, 73.8% yield) was obtained as a pale yellow solid.

[0254] Indoline 16: To a solution of 4-methyl-1H-indole-6-carbonitrile (600 mg, 3.84 mmol) in HOAc (15 mL) was added NaBH3CN (1.45 g, 23.0 mmol). The mixture was stirred at 25 °C for 12 h. The reaction mixture was added to saturated aqueous Na2CO3 until the pH was about 8. The mixture was diluted with H2O (300 mL) and extracted with EtOAc (150 mL × 3). The combined organic layers were washed with brine (300 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1:0 to 0:1). 4-Methylindoline-6-carbonitrile (250 mg, 1.20 mmol, 31.2% yield) was obtained as a pale yellow solid. [ka]

[0255] Indoline 18: A mixture of 4-bromoindoline (0.5 g, 2.52 mmol), 2-isopropenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (509.0 mg, 3.03 mmol), CsCO (1.23 g, 3.79 mmol), Pd(dppf)Cl (184.7 mg, 252.4 μmol) in dioxane (10 mL) and HO (2 mL) was degassed and purged with N three times, then the mixture was stirred at 110 °C under N atmosphere for 12 h. The reaction mixture was diluted with HO (20 mL) and extracted with DCM (60 mL × 3). The combined organic layers were washed with saturated brine (20 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=1:0 to 10:1). 4-Isopropenylindoline (60 mg, 376.8 μmol, 14.9% yield) was obtained as a yellow solid. [ka]

[0256] Indoline 20: To a mixture of 4-bromoindoline (1 g, 5.05 mmol) and 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (933 mg, 6.06 mmol) in dioxane (10 mL) and HO (2 mL), Pd(dppf)Cl2 (369 mg, 504.9 μmol) and Cs2CO3 (2.47 g, 7.57 mmol) were added at 15 °C under N2. The mixture was heated to 110 °C and stirred for 12 h. The residue was diluted with HO (120 mL) and extracted with EtOAc (60 mL × 2). The combined organic layers were washed with 120 mL of brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give the residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1:0 to 10:1). 4-Vinylindoline (400 mg, 2.45 mmol, 48.6% yield) was obtained as a yellow oil. [ka]

[0257] Indoline 22: To a solution of 4-bromoindoline (0.5 g, 2.52 mmol) in dioxane (10 mL) and H2O (1 mL) was added cyclopropylboronic acid (433.6 mg, 5.05 mmol), di-Cesium;carbonate (1.65 g, 5.05 mmol), and cyclopentyl(diphenyl)phosphane;dichloropalladium;iron (184.7 mg, 252.4 μmol). The mixture was stirred at 110 °C for 12 h under N2 atmosphere. The reaction mixture was diluted with 15 mL of H2O and extracted with EtOAc (40 mL × 2). The combined organic layers were washed with 20 mL of saturated brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1:0 to 10:1). 4-Cyclopropylindoline (0.1 g, 628 μmol, 24.8% yield) was obtained as a yellow oil.

[0258] Example 41 This example demonstrates that exemplary compounds of the invention inhibit ROCK1 and / or ROCK2 enzyme activity.

[0259] Dose-response curves for compounds of the invention were determined using a fluorescence-coupled enzyme assay using purified C-terminally truncated human ROCK1 catalytic domain (amino acids 1-477 of accession number NP_005397.1) fused to GST (Carna BioSciences, catalog number 01-109) and purified C-terminally truncated human ROCK2 enzyme kinase domain (amino acids 1-553 of accession number NP_004841.2) fused to GST (Carna BioSciences, catalog number 01-110). Additionally, full length cGMP-dependent protein kinase 1 (PKG or PRKG1, amino acids 1-686 of accession number NP_006249.1) fused to GST (Carna BioSciences, catalog number 01-142), full length PKACα (PRKACA, amino acids 1-351 of accession number NP_002721.1) fused to GST (Carna BioSciences, catalog number 01-127), and a C-terminally truncated human AKT1 catalytic domain (amino acids 104-480 of accession number NP_005154.1) fused to GST (Carna BioSciences, catalog number 01-101) were used as controls to measure any undesired off-target kinase activity.

[0260] Briefly, compounds of the invention were solubilized in DMSO and a series of 12 3-fold serial dilutions were performed for each compound in 2.5% DMSO. The initial starting concentration of each compound serial dilution was 10 μM or 100 μM. Control samples lacking compound, ROCK enzyme, or ATP were also prepared and processed in parallel with the compound test samples.

[0261] Aliquots of 4 μL of each of a series of dilutions of test compounds diluted in HO containing 2.5% DMSO were added to wells containing 4 μL of 10 nM purified N-truncated ROCK1 (4 nM final concentration), 10 nM purified N-truncated ROCK2 enzyme (4 nM final concentration), 1.25 nM AKT1 (0.5 nM final concentration), 25 pM PKACA (10 pM final concentration), or 20 nM PKG (8 nM final concentration) in reaction buffer containing 50 mM Hepes (pH 7.5), 1 mM EGTA, 10 mM MgCl, 2 mM DTT, and 0.01% Tween 20 (final concentration). To initiate the enzymatic reaction, 2 μL of solution was added to each well resulting in a final concentration of 50 nM Ulight-CREBTide peptide substrate (Perkin Elmer, Cat. No. TRF0107) and 4 pM ATP for ROCK1 and AKT1 assays, 8 pM ATP for ROCK2 assay, and 30 pM ATP for PKG assay, or 1 pM ATP for PKACA assay. The reaction mixture was incubated for 1 h at room temperature. After 1 h, the reaction was stopped by adding a 10 μL solution of europium-labeled phospho-CREB (Ser133) antibody (Perkin Elmer, Cat. No. TRF0200) in LANCE buffer supplemented with 20 mM EDTA. The stopped reaction mixture was incubated for 90 min at room temperature. The TR-FRET 665 / 620 ratio was determined using a Clariostar monochromator plate reader instrument (BMG LabTech) according to the manufacturer's instructions. The IC of each compound was determined using a 10 μL solution of europium-labeled phospho-CREB (Ser133) antibody (Perkin Elmer, Cat. No. TRF0200) in LANCE buffer supplemented with 20 mM EDTA. 50 IC values ​​were determined from each dose-response curve using GraphPad Prism7 software with a sigmoidal dose response. Results for exemplary compounds of formula (I) and formula (II) are shown in Table 1. Key: A is the IC 50 ≦100 nM, and B is 100 nM <IC 50 <1,000 nM, C is 1,000 <IC 50 ≦10,000 nM, and D is the IC 50 >10,000nM. [Table 1]

[0262] While the invention has been described in relation to specific embodiments thereof, it will be understood that it is capable of further modifications, and this application is intended to cover any variations, uses, or adaptations of the invention in accordance with the principles of the invention, within known or customary practice in the art to which the invention pertains, which may be applied to the essential features described above, including departures from the present disclosure as follows in the appended claims.

Claims

1. Formula (Ia), Formula (Ib), Formula (IIa), or Formula (IIb): 【Chemistry 1】 [In the formula, The structure: 【Chemistry 2】 has the following structure: 【Chemistry 3】 is selected from the group consisting of Y is N or CH; Each R １ are independently halogen, -CN, C １ ~C ３ Alkyl, haloalkyl, alkyl-OH, -N(R ４ ) ２ , -NR ４ C(O)C １ ~C ３ alkyl, -OH, -O-alkyl, or cycloalkyl; R ２ is H or a halogen; R ３ is H, halogen, or C １ ~C ３ is alkyl, Each R ４ are independently H or C １ ~C ３ is alkyl, m is 0, 1, 2, or 3. or a pharma- ceutically acceptable salt thereof.

2. The structure: 【Chemistry 4】 has the following structure: 【Chemistry 5】 Selected from the group consisting of:

2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof.

3. The structure: 【Chemistry 6】 has the following structure: 【Chemistry 7】 That is, 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof.

4. 4. The compound of claim 3, wherein m is 1, or a pharma- ceutically acceptable salt thereof.

5. R １ The compound according to claim 1 , wherein is chlorine or fluorine.

6. R １ The compound of claim 1 , wherein is trifluoromethyl.

7. The -N(R ４ ) ２ Each R ４ The compound of claim 1 , wherein the group is H.

8. The -N(R ４ ) ２ Each R ４ The group is C １ ~C ３ The compound of claim 1 , wherein the aryl group is an alkyl group.

9. R １ The compound of claim 1 , wherein is hydroxymethyl.

10. R １ The compound of claim 1 , wherein is cyclopropyl.

11. m is 2, and each R １ are independently -CN, halogen, C １ ~C ３ The compound of claim 3, which is alkyl, or cycloalkyl.

12. Each R １ The compound of claim 11 , wherein is a halogen.

13. On the other hand, R １ is -CN, and the other R １ is -OH, alkyl-OH, halogen, haloalkyl, -O-alkyl, C １ ~C ３ Alkyl, -N(R ４ ) ２ , -NR ４ C(O)C １ ~C ３ 12. The compound of claim 11, which is alkyl, or cycloalkyl.

14. The structure: 【Chemistry 8】 has the following structure: 【Chemistry 9】 2. The compound of claim 1 , 15. The structure: 【Chemistry 10】 has the following structure: 【Chemistry 11】 15. The compound of claim 14, wherein

16. R ２ The compound according to any one of claims 1 to 15, wherein is halogen.

17. 17. The compound of claim 16, wherein the halogen is chlorine.

18. R ３ is halogen or C １ ~C ３ The compound according to any one of claims 1 to 17, which is alkyl.

19. 20. The compound of claim 18, wherein the halogen is fluorine.

20. Said C １ ~C ３ 20. The compound of claim 18, wherein the alkyl is methyl.

21. The compound is 【Chemistry 12-1】 【Chemistry 12-2】 【Chemistry 12-3】 2. The compound of claim 1 selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

22. A pharmaceutical composition comprising an effective amount of a compound according to any one of claims 1 to 21, and a pharma- ceutically acceptable excipient.

23. A pharmaceutical composition for use in a method for inhibiting ROCK activity in a cell, comprising: The method includes contacting the cell in which inhibition of ROCK activity is desired with a therapeutically effective amount of a compound of claim 1; and 13. The pharmaceutical composition comprising the compound of claim 1 or a pharma- ceutically acceptable salt thereof.

24. 24. The pharmaceutical composition of claim 23, wherein the contacting occurs in vivo.

25. 25. The pharmaceutical composition of claim 23 or 24, wherein the therapeutically effective amount of the compound is 0.01 to 300 mg / kg per day.

26. 26. The pharmaceutical composition of claim 25, wherein the therapeutically effective amount of the compound is 0.1-100 mg / kg per day.

27. 1. A pharmaceutical composition for use in a method for treating a patient having cerebral cavernous hemangioma syndrome (CCM), comprising: The method comprises administering to the patient a therapeutically effective amount of a compound of claim 1, alone or in combination with a pharma- ceutically acceptable carrier, excipient, or diluent; and 13. The pharmaceutical composition comprising the compound of claim 1 or a pharma- ceutically acceptable salt thereof.

28. 28. The pharmaceutical composition of claim 27, wherein the therapeutically effective amount of the compound is 0.01-300 mg / kg per day.

29. 29. The pharmaceutical composition of claim 28, wherein the therapeutically effective amount of the compound is 0.1-100 mg / kg per day.

30. 1. A pharmaceutical composition for use in a method for treating a cardiovascular disease associated with increased vascular tone, comprising: The method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1, alone or in combination with a pharma- ceutically acceptable carrier, excipient, or diluent; and 13. The pharmaceutical composition comprising the compound of claim 1 or a pharma- ceutically acceptable salt thereof.

31. 31. The pharmaceutical composition of claim 30, wherein the cardiovascular disease is hypertension, atherosclerosis, ischemic stroke, coronary vasospasm, cerebral vasospasm, angina pectoris, or erectile dysfunction.

32. 1. A pharmaceutical composition for use in a method for treating a disease associated with elevated non-vascular smooth muscle contractility, comprising: The method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1, alone or in combination with a pharma- ceutically acceptable carrier, excipient, or diluent; and 13. The pharmaceutical composition comprising the compound of claim 1 or a pharma- ceutically acceptable salt thereof.

33. 33. The pharmaceutical composition of claim 32, wherein the disease associated with elevated non-vascular smooth muscle contractility is asthma or glaucoma.

Images